Harald Jurgen Hampel, Md, Phd, Ma, Msc
Harald Jurgen Hampel, Md, Phd, Ma, Msc
Professor of Neurology

Sorbonne Universites
France

Education

Professional Degrees:

  • 1994- M.D., University of Munich, Germany
  • 1996- Ph.D., University of Munich, Germany
  • 2007- M.Sc., University of Cologne (KFH), Germany
  • 2008- M.A., Trinity College, University of Dublin, Ireland

Certifications

  • 1994 - Licence to practise as a physician (approbation)
  • 2002 - Licence as Consultant in General Adult Psychiatry and Psychotherapy
  • 2005 - Licence as Consultant in Clinical Geriatrics (FW)
  • 2006 - Full registration as Medical Specialist in Ireland in General Adult     Psychiatry and Psychiatry of Later Life, Medical Council Ireland
  • 2008 - Appointment as Professorial Fellow of Trinity College, University of Dublin, Ireland

 

Profile

 

Research Interest

Discovery, development and validation of novel therapies and multimodal biomarker candidates using biochemical (blood & CSF) and structural, functional & metabolic neuroimaging methods in mono- and multi-site studies for risk assessment, progression, prediction, detection, diagnosis and classification of neurodegenerative diseases (focus on Alzheimer's disease [AD]) at different disease stages. Detection of genetic risk & protection variants in large-scale international research networks.

 

Professional Activities:

Professional Experience:

1993 – 1995

Resident & Chief Resident, Department of Psychiatry, University of Munich, Germany

1995 - 1997

Postdoctoral Fellow, NIH, NIA, Laboratory of Neurosciences, Bethesda, USA

2001 - 2009

Founding Director, Alzheimer Memorial Center, University of Munich

2005 - 2007

Full Professor of Psychiatry, Department of Psychiatry, University of Munich, Germany

2007 - 2009

Full tenured Professor & Chair of Psychiatry, PI at Trinity College
Institute of Neuroscience, Trinity College, University of Dublin, Ireland

2010 - 2013

Full tenured Professor & Chair of Psychiatry, Head of Department of Laboratory of Neuroscience, Alzheimer Research Center, Co-director of the Brain Imaging Center (BIC), Goethe University, Frankfurt/Main, Germany

2013 -ongoing

Full tenured Professor & AXA Research Fund & UPMC Excellence Chair, Sorbonne Universités, Université Pierre et Marie Curie, Institut de la Mémoire et de la Maladie d’Alzheimer & Institut du Cerveau et de la Moelle épinière (ICM), Département de Neurologie, Hôpital de la Salpêtrière, Paris, France

Honorary Professorships

2007-2011

Visiting Professor

University of Munich, Germany

2009-2011

Adjunct Professor

Trinity College, University of Dublin, Ireland

2013-permanent

Visiting Professor

University of Belgrade, Serbia

 

Honors and Awards

Publications

Original Publications (including Scientific Impact Factors) Co-Author

a)      Original Publications (accepted, in press, published) (291)
Cumulative Scientific Impact Factor Original Publications (print, Epub ahead of print, accepted): 995.831
aa) First/Second/Senior Author (111) (453.893)
  1. Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, Jessen F, Herukka SK, Soininen H, Maetzler W, Leyhe T, Bürger K, Taniguchi M, Urakami K, Lista S, Dubois B, Blennow, Harald H. Differential diagnosis of Alzheimer’s disease using cerebrospinal fluid biomarkers. A large-scale international multi-center study. Alzheimers Dement. IF=17.472
  2. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, Li R, Shen Y. Increased  Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer's Disease. J Alzheimers Dis. 2014 Jan 1;41(3):877-86 (IF 4.174).
  3. Schwarz M, Guillemin GJ, Teipel SJ, Buerger K, Hampel H. Increaed 3-Hydroxykynurenine serum concentrations differenziate Alzheimer’s disease patients from controls. Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):345-52. (IF 3.494).
  4. O'Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H. Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: A MRI Study. PLoS One. 2012;7(11):e48895. Epub 2012 Nov 9. (IF 4.411).
  5. O’Dwyer L, Lamberton F, Bokde A, Ewers M, Faluyi Y, Tanner C, Mazoyer B, O’Neill D, Bartley M, Coughlan T, Collins R, Prvulovic D, Hampel H. Sexual dimorphism in healthy aging and mild cognitive impairment: a DTI study. PLoS One. 2012;7(7):e37021. Epub 2012 Jul 2. (IF 4.411).
  6. O’Dwyer L, Lamberton F, Matura S, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H. White matter differences between healthy young ApoE4 carrier and non-carriers identified with tractography and support vector machines. PloS One. 2012 7(4):e36024.  Epub 2012 Apr 25. (IF 4.411)
  7. O’Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO. Tanner C, Mazoyer B, O’Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, Hampel H. Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PloS One. 2012; 7(2):e32441. Epub 2012 Feb 23. (IF 4.411).
  8. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H. Amyloid- oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer’s disease. J Alzheimers Dis. 2012; 29(1):171-6. Epub 2012 Jan 3. (IF 4.261).
  9. Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller HJ, Teipel SJ, Ernst A, Bergmann A, Hampel H. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiat. 2011; 72(4):556-63. Epub 2010 Nov 2. (IF 5.023).
  10. Ewers M, Cheng X, Zhong Z, Nural HF, Walsh C, Meindl T, Teipel SJ, Buerger K, He P, Shen Y, Hampel H. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease. J Alzheimers Dis. 2011; 25(2):373-81. Epub 2011 Apr 1. (IF 4.261).
  11. Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthun L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging. 2011 Jun 16. [Epub ahead of print] (IF 6.634).
  12. O’Dwyer L, Lamberton F, Bokde ALW, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O’Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, Hampel H. Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer’s disease. PLoS One. 2011; 6(6): e21745. Epub 2011 Jun 30. (IF 4.411).
  13. O’Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O’Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, Hampel H. Using diffusion tensor imaging and mixed-effects models to investigate primary and secondary white matter degeneration in Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis. 2011; 26(4):667-82. Epub 2011 Jun 21. (IF 4.261).
  14. Schneider P, Buerger K, Teipel S, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Rujescu D, Moeller HJ, Zetterberg H, Blennow K, Ernst A, Bergmann A, Hampel H. Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer’s disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiat. 2011; 70(2):145-51. Epub 2011 Mar 31. (IF 8.674)
  15. Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, Reiser MF, Möller HJ, Heinsen H, Hampel H. The cholinergic system in mild cognitive impairment and Alzheimer’s disease: An in vivo MRI and DTI study. Human Brain Mapp. 2011; 32(9):1349-62. Epub 2010 Jul 29. (IF 5.107)
  16. Teipel SJ, Reuter S, Stieltjes B, Acosta-Cabronero J, Ernemann U, Fellgiebel A, Filippi M, Frisoni G, Hentschel F, Jessen F, Klöppel S, Meindl T, Pouwels PJ, Hauenstein KH, Hampel H. Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiat Res-Neuroim. 2011; 194(3):363-71. Epub 2011 Nov 9. (IF 2.064)
  17. Bokde AL, Karmann M, Born C, Teipel SJ, Omerovic M, Ewers M, Frodl T, Meisenzahl E, Reiser M, Möller HJ, Hampel H. Altered brain activation during a verbal working memory task in subjects with amnestic mild cognitive impairment. J Alzheimers Dis. 2010; 21(1):103-18. (IF 3.832)
  18. Bokde AL, Lopez-Bayo P, Born C, Ewers M, Meindl T, Teipel SJ, Faltraco F, Reiser M, Möller HJ, Hampel H. Alzheimer disease: Functional abnormalities in the dorsal visual pathway in Alzheimer’s disease patients. Radiology. 2010; 254(1):219-26. (IF 6.341)
  19. Ernst A, Buerger K, Hartmann O, Dodel R, Noelker C, Sommer N, Schwarz M, Köhrle J, Bergmann A, Hampel H. Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. J Neuroimmunol. 2010; 221(1-2):62-7. (IF 2.841)
  20. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr., Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H; North American Alzheimer’s Disease Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neubiol Aging. 2010 Dec 13. [Epub ahead of print] (IF 5.937)
  21. Haberstroh J, Hampel H, Pantel J. Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice. Neuropsychiatr Dis Treat. 2010; 6(1):243-53. (IF -)
  22. Prvulovic D, Hampel H. ¿Un cambio de paradigma en el diagnóstico psiquiátrico moderno? Anomalías en las redes neuronales como concepto fisiopatológico y nueva herramienta de diagnóstico [A paradigm shift in modern psychiatric diagnosis? Neural network dysfunction as a pathophysiological concept and novel diagnostic tool]. Rev Psyquiatr Salud Ment (Barc) 2010; 3(4):115-8. (IF -)
  23. Teipel SJ, Bokde ALW, Meindl T, Amaro E Jr, Soldner J, Reiser MF, Herpertz SC, Moeller HJ, Hampel H. White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage. 2010; 49(3):2021-32. (IF 5.739)
  24. Teipel SJ, Ewers M, Wolf S, Jessen F, Kölsch H, Arlt S, Luckhaus C, Schoenknecht P, Schmidtke K, Heuser I, Frölich L, Ende G, Pantel J, Wiltfang J, Rakebrandt F, Peters O, Born C, Kornhuber J, Hampel H. Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer’s disease. Psychiat Res-Neuroim. 2010; 182(3):244-50. (IF 3.435)
  25. Teipel SJ, Meindl T, Wagner M, Stieltjes B, Reuter S, Hauenstein KH, Filippi M, Ernemann U, Reiser MF, Hampel H. Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis. 2010; 22(2):507-22. (IF 3.832)
  26. Amann B, Pantel J, Grunze H, Vieta E, Colom F, Gonzalez-Pinto A, Naber D, Hampel H. Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clin Pract Epidemiol Ment Health. 2009; 5(1):14. (IF 1.430)
  27. Bokde ALW, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, Moeller HJ, Hampel H. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. J Clin Psychopharm. 2009; 29(2):147-56. (IF 4.371)
  28. Buerger K, Ernst A, Ewers M, Uspenskaya O, Omerovic M, Morgenthaler NG, Knauer K, Bergmann A, Hampel H. Blood-based microcirculation markers in Alzheimer’s disease – diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiat. 2009; 65(11):979-84. (IF 8.627)
  29. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H. Validation of Alzheimer’s disease CSF and plasma biological markers – the multi-center reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI). Exp Geront. 2009; 44(9):579-85. (IF 3.283)
  30. Hampel H, Broich K. Enrichment of MCI and early Alzheimer’s disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging. 2009; 13(4):373-5. (IF 2.321)
  31. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe M, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiat. 2009; 70(6):922-31. (IF 5.053)
  32. Teipel SJ, Meindl T, Wagner M, Kohl T, Bürger K, Reiser MF, Herpertz S, Möller HJ, Hampel H. White matter microstructure in relation to education in aging and Alzheimer’s disease. J Alzheimers Dis. 2009; 17(3):571-83. (IF 5.101)
  33. Teipel SJ, Pogarell O, Meindl T, Dietrich O, Sydykova D, Hunklinger U, Georgii B, Mulert C, Reiser MF, Möller HJ, Hampel H. Regional networks underlying interhemispheric connectivity: An EEG and DTI study in healthy ageing and amnestic mild coginitive impairment. Human Brain Mapp. 2009; 30(7):2098-119. (IF 5.395)
  34. Bokde ALW, Lopez-Bajo P, Born C, Dong W, Meindl T, Leinsinger G, Teipel SJ, Faltraco F, Reiser M, Möller HJ, Hampel H. Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: an fMRI study. Psychiat Res-Neuroim. 2008; 163(3):248-59. (IF 2.666)
  35. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H. Increased CSF-BACE1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer’s disease. Brain. 2008; 131(5):1252-8. (IF 9.603)
  36. Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, Herholz K, Heiss WD, Hampel H. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease. Eur J Neurol. 2008; 15(11):1155-62. (IF 2.732)
  37. Buerger K, Alafuzoff I, Ewers M, Pirttilä T, Zinkowski R, Hampel H. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain. 2007; 130(10):e82. (IF 8.568)
  38. Ernst A, Morgenthaler NG, Buerger K, Dodel R, Noelker C, Sommer N, Schwarz M, Koehrle J, Bergmann A, Hampel H. Procalcitonin is elevated in the cereobrospinal fluid of patients with dementia and acute neuroinflammation. J Neuroimmunol. 2007; 189(1-2):169-74. (IF 2.920)
  39. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroeder J, Zinkowski R, Bouwman FH, Schoenknecht P, Schoonenboom NSM, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology. 2007; 69(24):2205-12. (IF 6.014)
  40. Teipel SJ, Bokde ALW, Born C, Meindl T, Reiser M, Möller HJ, Hampel H. Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. Brain. 2007; 130(7):1745-58. (IF 8.568)
  41. Teipel SJ, Born C, Ewers M, Bokde ALW, Reiser MF, Möller HJ, Hampel H. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer’s disease in mild cognitive impairment. Neuroimage. 2007; 38(1):13-24. (IF 5.559)
  42. Teipel SJ, Mitchell AJ, Moeller HJ, Hampel H. Improving linear modeling of cognitive decline in patients with mild cognitive impairment: comparison of two methods. J Neural Transm Suppl. 2007; 72:241-7. (IF 2.672)
  43. Teipel SJ, Stahl R, Dietrich O, Schoenberg SO, Perneczky R, Bokde ALW, Reiser MF, Moeller HJ, Hampel H. Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage. 2007; 34(3):985-95. (IF 5.559)
  44. Bokde ALW, Lopez-Bayo P, Meindl T, Pechler S, Born C, Faltraco F, Teipel SJ, Möller HJ, Hampel H. Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain. 2006; 129(5):1113-24. (IF 7.617)
  45. Buerger K, Otto M, Teipel S, Zinkowski R, Blennow K, DeBernardis J, Kerkman, D, Schröder J, Schönknecht P, Cepek L, McCulloch C, Möller HJ, Wiltfang J, Kretzschmar H, Hampel H. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging.2006; 27(1):10-5.(IF 5.599)
  46. Bürger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain. 2006; 129(11):3035-41. (IF 7.617)
  47. Ewers M, Teipel SJ, Dietrich O, Schönberg SO, Jessen F, Heun R, Scheltens P, van de Pol L, Freymann NR, Möller HJ, Hampel H. Multicenter assessment of reliability of cranial MRI. Neurobiol Aging. 2006; 27(8):1051-9.(IF 5.599)
  48. Heinsen H, Hampel H, Teipel SJ. Computer-assisted 3D reconstruction of the nucleus basalis complex, including nucleus subputaminalis (Ayala’s nucleus), in response to the suggestions of Boban et al. Brain. 2006; 129:E43. (IF 7.617)
  49. Teipel SJ, Drzezga A, Bartenstein P, Möller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer’s disease: a double-blind cross-over trial. Psychopharmacology (Berl.). 2006; 187(1):86-94. (IF 3.625)
  50. Teipel SJ, Ewers M, Dietrich O, Schoenberg SO, Jessen F, Heun R, Freymann N, Moeller HJ, Hampel H. Reliability of multicenter magnetic resonance imaging. Results of a phantom test and in vivo measurements by the German Dementia Competence Network. [Multizentrische Reliabilität MRT-gestützter Volumetrie des Gehirns: Ergebnisse des Phantomtests und voxelbasierter Morphometrie im Kompetenznetz Demenzen]. Nervenarzt. 2006; 77(9):1086-92. (IF 0.711)
  51. Teipel SJ, Prüssner JC, Faltraco F, Born C, Rocha-Unold M, Evans A, Möller HJ, Hampel H. Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J Neurol. 2006; 253(6):794-800. (IF 2.984)
  52. Teipel SJ, Willoch F, Ishii K, Buerger K, Drzezga A, Engel R, Bartenstein P, Moeller HJ, Schwaiger M, Hampel H. Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiol Aging. 2006; 27(5):681-90. (IF 5.599)
  53. Bokde A, Dong W, Born C, Leinsinger G, Meindl T, Teipel SJ, Reiser M, Hampel H. Task difficulty in a simultaneous face matching task modulates activity in face fusiform area. Brain Res Cogn Brain Res. 2005; 25(3):701-10. (IF 2.471)
  54. Bokde ALW, Teipel SJ, Drzezga A, Thissen J, Bartenstein P, Dong W, Leinsinger G, Born C, Schwaiger M, Moeller HJ, Hampel H. Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer's disease. Dement Geriatr Cogn. 2005; 20(6):352-7. (IF 2.603)
  55. Bokde ALW, Teipel SJ, Schwarz R, Leinsinger G, Bürger K, Möller T, Möller HJ, Hampel H. Reliable manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic resonance images of healthy subjects. Brain Res Brain Res Protoc. 2005; 14(3):135-45. (IF 1.816)
  56. Brettschneider S, Morgenthaler N, Teipel SJ, Fischer-Schulz C, Bürger K, Dodel R, Du Y, Möller HJ, Bergmann A, Hampel H. Decreased serum amyloid ß1-42 autoantibody levels in AD, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid ß1-42 peptide. Biol Psychiat. 2005; 57:813-6. (IF 6.779)
  57. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, Teipel SJ, Graz C, Blennow K, Hampel H. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study. Neurology. 2005; 65(9):1502-3. (IF 5.065)
  58. Buerger K, Teipel S, Zinkowski R, Sunderland T, Andreasen N, Blennow K, Ewers M, DeBernardis J, Shen Y, Kerkman D, Du Y, Hampel H. Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. Neurosci Lett, 2005, 391:48-50. (IF 1.898)
  59. Hampel H, Bürger K, Pruessner J, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans A, Davies P, Möller HJ, Teipel SJ. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005; 62:770-3. (IF 4.900)
  60. Hampel H, Haslinger A, Scheloske M, Padberg F, Fischer P, Unger J, Teipel SJ, Neumann M, Rosenberg C, Oshida R, Hulette C, Pongratz D, Ewers M, Kretzschmar HA, Möller HJ. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer’s disease brain, Eur Arch Psy Clin N. 2005; 255:269-78. (IF 2.264)
  61. Pogarell O, Teipel SJ, Juckel G, Gootjes L, Möller T, Bürger K, Leinsinger G, Möller HJ, Hegerl U, Hampel H. EEG coherence reflects regional corpus callosum area in Alzheimer’s disease. J Neurol Neurosur Ps. 2005; 76:109-11. (IF 3.122)
  62. Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stöckel S, Dietrich O, Reiser MF, Möller HJ, Hampel H. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain. 2005; 128(11):2626-44. (IF 7.535)
  63. Gootjes L, Teipel SJ, Zebuhr Y, Schwarz R, Wismüller A, Leinsinger G, Scheltens P, Möller HJ, Hampel H. Regional Distribution of White Matter Hypertintensities in Vascular Dementia, Alzheimer’s disease and Healthy Aging.Dement Geriatr Cogn. 2004; 18:180-8. (IF 2.493)
  64. Hampel H, Buerger K, Zinkowski R, Goernitz A, Teipel SJ, Andreasen N, Sjogren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Möller HJ, Davies P, Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer’s disease – a comparative CSF study.Arch Gen Psychiat. 2004; 61(1):95-102. (IF 11.207)
  65. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K. Value of CSF ß-Amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatr. 2004; 9:705-10. (IF 6.943)
  66. Teipel SJ, Alexander G, Schapiro M, Möller HJ, Rapoport S, Hampel H. Age-related cortical grey matter reductions in nondemented Down's syndrome adults determined by magnetic resonance imaging with voxel-based morphometry. Brain. 2004; 127(4):811-24. (IF 8.201)
  67. Bürger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, McCulloch C, Padberg F, Faltraco F, Goernitz A, Tapiola T, Rapoport SI, Pirttilä T, Möller HJ, Hampel H. Differentiation of Geriatric Major Depression from Alzheimer’s Disease with CSF Tau Protein Phosphorylated at Threonine 231. Am J Psychiat. 2003; 160:376-9. (IF 7.157)
  68. Faltraco F, Bürger K, Zill P, Teipel SJ, Bondy B, Ackenheil M, Möller HJ, Hampel H. Interleukin-6-174 G/C Promoter Gene Polymorphism C allele reduces Alzheimer’s Disease Risk.J Am Geriatr Soc. 2003; 51(4):578-9. (IF 2.835)
  69. Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, Sjogren M, Zetterberg H, Forsell L, Lilius L, Wahlund LO, Rymo L, Prince JA, Blennow K. Increased frequency of a new polymorphism in cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia, Neurosci Lett. 2003; 340(1):69-73. (IF 1.967)
  70. Teipel SJ, Bayer W, Alexander GE, Bokde ALW, Zebuhr Y, Teichberg D, Müller-Spahn F, Schapiro F, Möller HJ, Rapoport SI, Hampel H. Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer's disease in relation to dementia severity – evidence for early neocortical degeneration, Neurobiol Aging. 2003; 24(1):85-94. (IF 5.552)
  71. Teipel SJ, Schapiro MB, Alexander GE, Krasuski JS, Horwitz B, Hoehne C, Möller HJ, Rapoport SI, Hampel H. Relation of corpus callosum and hippocampus size to age in nondemented adults with Down's syndrome. Am J Psychiat. 2003; 160(10):1870-8. (IF 7.157)
  72. Bokde ALW, Teipel SJ, Zebuhr Y, Leinsinger G, Gootjes L, Schwarz R, Buerger K, Scheltens P, Möller HJ, Hampel H. A new rapid landmark-based regional MRI segmentation method of the brain. J Neurol Sci. 2002; 194(1):35-40. (IF 2.080)
  73. Bürger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Möller HJ, Davies P, Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002; 59(4): 627-9. (IF 5.340)
  74. Bürger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Hofmann-Kiefer K, DeBernardis J, Kerkman D, Miller C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H. Differential diagnosis of Alzheimer's diesease with CSF tau protein phosphorylated at threonine 231, Arch Neurol. 2002; 59(8):1267-72. (IF 4.336)
  75. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Human antibodies against amyloid b-peptide: a potential treatment for Alzheimer’s disease, Ann Neurol. 2002; 52(2):253-6. (IF 8.603)
  76. Frodl T, Hampel H, Juckel G, Bürger K, Padberg F, Engel RR, Möller HJ, Hegerl U. Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer’s disease. Psychophysiology. 2002; 39:175-81. (IF 2.674)
  77. Hampel H, Teipel SJ, Alexander GE, Pogarell O, Rapoport SI, Möller HJ. In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer’s disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. J Neural Transm. 2002; 109(5-6):837-55. (IF 2.289)
  78. Hampel H, Teipel SJ, Bayer W, Alexander GE, Schwarz R, Schapiro MB, Rapoport SI, Möller HJ. Age-transformation of combined hippocampus amygdala volume improves diagnostic accuracy in Alzheimer’s disease. J Neurol Sci. 2002; 194(1):15-9. (IF 2.080)
  79. Bürger K, Mergner R, Arbusov V, Padberg F, Hampel H. Late onset Huntington's disease – a differential diagnosis of Alzheimer's disease. [Chorea Huntington mit später Manifestation als Differentialdiagnose der Alzheimer-Krankheit]. Nervenarzt. 2002; 73:870-3. (IF 0.886)
  80. Teipel SJ, Bayer W, Alexander GE, Alexander GE, Zebuhr Y, Teichberg D, Kulic L, Schapiro MB, Möller HJ, Rapoport SI, Hampel H. Progression of corpus callosum atrophy in Alzheimer’s disease, Arch Neurol. 2002; 59:243-8. (IF 4.336)
  81. Hampel H, Bürger K, Kohnken R, Teipel SJ, Zinkowski R, Möller HJ, Rapoport SI, Davies P. Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol. 2001; 49(4):545-6. (IF 8.481)
  82. Hampel H, Kötter HU, Padberg F, Berger C. Severe Hirsutism associated with psychopharmacological treatment in major depression. World J Biol Psychia. 2001; 2:48-9. (IF 2.800)
  83. Padberg F, Haase CG, Feneberg W, Schwarz MJ, Hampel H. No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum / cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosis. Neurosci Lett. 2001; 305(1):13-6. (IF 2.021)
  84. Satzger W, Hampel H, Padberg, F, Bürger K, Nolde T, Ingrassia G, Engel RR. Zur praktischen Anwendung der CERAD-Testbatterie als neuropsychologisches Demenzscreening. Nervenarzt. 2001; 72:196-203. (IF 0.916)
  85. Hampel H, Teipel SJ, Alexander GE, Horwitz B, Pietrini P, Hippius H, Möller HJ, Schapiro MB, Rapoport SI. Corpus callosum measurement as an in-vivo indicator for neocortical neuronal integrity, but not white matter pathology, in Alzheimer’s disease. Ann NY Acad Sci. 2000; 903:470-7. (IF 1.381)
  86. Kohnken R, Buerger K, Zinkowski R, Kerkman D, DeBernardis J, Shen J, Möller HJ, Davies P, Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid. Neurosci Lett. 2000; 287(3):187-90. (IF 2.091)
  87. Berger C, Vetter H, Möller HJ, Hampel H. Beeinflussung der Phenprocoumonwirkung durch trizyklische Antidepressiva. Zeitschrift für Herz-, Thorax-, Gefäßchirurgie. 1999; 13:139-46. (IF -)
  88. Bürger K, Padberg F, Nolde T, Stübner S, Teipel SJ, Haslinger A, Boetsch T, Sunderland T, Arai H, Rapoport SI, Möller HJ, Hampel H. CSF tau protein discriminates between Alzheimer’s disease, major depression and healthy controls in young old, but not in old old. Neurosci Lett. 1999; 277(1):21-24. (IF 2.085)
  89. Ehrhardt T, Plattner A, Padberg F, Möller HJ, Hampel H. Verhaltenstherapeutische Behandlung eines Patienten mit beginnender Alzheimer Demenz. Verhaltenstherapie. 1999; 9:154-61. (IF 0.463)
  90. Hampel H, Kötter HU, Padberg F, Körschenhausen D, Möller HJ. Oligoclonal bands and blood-cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alz Dis Assoc Dis. 1999; 13(1):9-19. (IF 1.229)
  91. Hampel H, Teipel SJ, Padberg F, Haslinger A, Riemenschneider M, Schwarz MJ, Kötter HU, Scheloske M, Buch K, Stübner S, Dukoff R, Lasser R, Müller N, Sunderland T, Rapoport SI, Möller HJ. Discriminant power of combined cerebrospinal fluid tau protein and soluble gp130 in the diagnosis of Alzheimer’s disease. Brain Res. 1999; 823(1-2):104-12. (IF 2.302)
  92. Möller HJ, Hampel H, Hegerl U, Schmitt W, Walter K. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry. 1999; 32(3):99-106. (IF 2.803)
  93. Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Körschenhausen DA, Greenberg BD, Nolde T, Müller N, Trappmann H, König N, Möller HJ, Hampel H. CSF and serum levels of soluble interleukin-6 receptors, but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol. 1999; 99:218-23. (IF 3.233)
  94. Stübner S, Schön T, Padberg F, Teipel SJ, Schwarz MJ, Haslinger A, Buch K, Dukoff R, Lasser R, Müller N, Sunderland T, Rapoport SI, Möller HJ, Hampel H. Interleukin-6 and the soluble interleukin-6 receptor are decreased in CSF of geriatric patients with major depression: No alteration of soluble gp130. Neurosci Lett. 1999; 259(3):145-8. (IF 2.085)
  95. Teipel SJ, Hampel H, Pietrini P, Alexander GE, Horwitz B, Daley E, Möller HJ, Schapiro MB, Rapoport SI. Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. Arch Neurol. 1999; 56(4):467-73. (IF 3.863)
  96. Hampel H, Sunderland T, Kötter HU, Schneider C, Dukoff R, Levy J, Möller HJ. Decreased soluble interleukin-6 receptor in CSF of patients with Alzheimer’s disease. Brain Res. 1998; 780(2):351-4. (IF 2.302)
  97. Hampel H, Teipel S, Alexander GE, Horwitz B, Teichberg D, Schapiro MB, Rapoport SI. Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: A magnetic resonance imaging analysis. Arch Neurol. 1998; 55:193-8. (IF 3.863)
  98. Padberg F, Stübner S, Buch K, Hegerl U, Hampel H. Pisa syndrome during treatment with sertindole. Brit J Psychiat, 1998, 173:351-2. (IF 4.093)
  99. Schwarz MJ, Müller N, Körschenhausen D, Kirsch KH, Penning R, Ackenheil M, Johnson JP, Hampel H. Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator Mader in normal human CNS. Neuroimmunomodulat. 1998; 5:270-6. (IF 1.609)
  100. Teipel SJ, Hampel H, Alexander GE, Horwitz B, Teichberg D, Möller HJ, Hippius H, Schapiro MB, Rapoport SI. Dissociation between regional pattern of corpus callosum atrophy and white matter pathology in Alzheimer’s disease. Neurology. 1998; 51:1381-5. (IF 5.232)
  101. Hampel H, Körschenhausen D, Schwarz M, Frenzel KH, Johnson JP, Penning R, Ackenheil M, Müller N. Detection of the novel cell adhesion molecule MUC18 in human brain tissue. Neuroimmunomodulat. 1997; 4:57-61. (IF 1.609)
  102. Hampel H, Kötter HU, Möller HJ. Blood-cerebrospinalfluid barrier dysfunction for high molecular weight proteins in Alzheimer’s disease and major depression: Indication for disease subsets. Alz Dis Assoc Dis. 1997; 11(2):78-87. (IF 1.229)
  103. Hampel H, Schoen D, Schwarz MJ, Kötter HU, Schneider C, Sunderland T, Dukoff R, Levy J, Padberg F, Stübner S, Buch K, Müller N, Möller HJ. Interleukin-6 CSF-levels are not altered in patients at risk and Alzheimer‘s disease. Neurosci Lett. 1997; 228:143-6. (IF 2.085)
  104. Hampel H, Berger C, Kuss H-J, Müller-Spahn F. Unstable anticoagulation in the course of amitripyline treatment. Pharmacopsychiatry. 1996; 29:33-7. (IF 2.803)
  105. Hampel H, Berger C, Müller N. A case of Ganser's state presenting as a dementia syndrome. Psychopathology. 1996; 29:236-41. (IF 0.425)
  106. Hampel H, Berger C, Müller-Spahn F, Ackenheil M. Modified oral anticoagulant potency in an amitryptilyne treated patient? Acta Hematol. 1996; 96:178-80. (IF 1.128)
  107. Hampel H, Schneider C, Hock C, Müller-Spahn F, Ackenheil M. CNS demyelination in monoclonal gammopathy of undetermined significance (MGUS): possible cause of a dementia syndrome. Eur Psychiat. 1996; 11:46-9. (IF 0.591)
  108. Körschenhausen D, Hampel H, Ackenheil M, Penning R, Wildenauer DB. Fibrin degradation products in post mortem brain tissue of schizophrenics: A possible marker for underlying inflammatory processes. Schizophr Res. 1996; 19:103-9. (IF 3.030)
  109. Hampel H, Berger C, Keiler B, Müller-Spahn F. Labile orale Antikoagulation unter Amitryptilintherapie. Herz, Kreislauf. 1995; 27(5):170-1. (IF 0.211)
  110. Hampel H, Müller-Spahn F, Haberl A, Berger C, Ackenheil M, Hock C. Evidence of blood-cerebrospinal-fluid-barrier-impairment in a subgroup of patients with dementia of the Alzheimer Type and major depression: a possible indicator for immunoactivation, Dementia. 1995; 6:348-54. (IF 1.737)
  111. Hampel H, Putz A, Müller N. Major Depression following Myiasis with hypereosinophilic syndrome. J Clin Psychiat. 1995; 56(7):333-4. (IF 4.172)

Co-Author (180) (571.586):

  1. Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, Helgason H, Sulem P, Magnusson O Th, Gudjonsson SA, Unnsteinsdottir U, Kong A, Helisalmi S, Soininen H,   Lah JJ, DemGene, Aarsland D, Fladby T, Ulstein ID, Djurovic S, Sando SB, White L, Knudsen GP, Westlye LT , Selbæk G, Hampel H, Hiltunen M, Levey AI, Andreassen OA, Rujescu D, Jonsson PV,  Bjornsson S,  Snaedal J, Stefansson K. Loss of function variants in ABCA7 confer risk of Alzheimer’s disease. Nat Genet. Accepted. IF=29.648.
  2. Levy Nogueira M, Lafitte O, Steyaert JM, Bakardjian H, Dubois B, Hampel H, Schwartz L. Mechanical stress related to brain atrophy in Alzheimer’s disease. Alzheimers Dement. 2014. Accepted. IF=17.472.
  3. Schulte EC, Kurz A, Alexopoulos P, Hampel H, Peters A, Gieger C, Rujescu D, Diehl-Schmid J, Winkel-mann J. Excess of rare coding variants in PLD3 in late- but not early- onset Alzheimer`s disease.  Human Genome Variation. IF= -
  4. Dubois B, ChupinM, Hampel H, Lista S, Cavedo E, Croisile B,Tisserand GL, Touchon J, Bonafe A, Ousset PJ, Ameur AA, Rouaud O, Ricolfi F, Vighetto A, Pasquier F, Delmaire C, Ceccaldi M,Girard N, Dufouil C, Lehericy S, Tonelli I, Duveau F, Colliot O, Garbero L,Sarazin M, Dormont D, and The “Hippo-campus Study Group”. Donepezil decreases annual rate of hippocampal atrophy in suspected prodro-mal AD. Alzheimers Dement. 2014. Accepted. IF=17.472
  5. Suppa P, Anker U, Spies L, Bopp I, Rüegger-Frey B, Klaghofer R, Gocke C, Hampel H, Beck S, Buchert R. Fully Automated Atlas-Based Hippocampal Volumetry for Detection of Alzheimer's Disease in a Memory Clinic Setting. J Alzheimers Dis. 2014 Sep 8. doi 10.3233/JAD-141446. (IF 3.612).
  6. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; for the Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry. 2014 Aug 27. doi: 10.1001/jamapsychiatry.2014.1060. (IF 13.77).
  7. Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci. 2014 Aug 26. doi: 10.1007/s00406-014-0521-9. IF=3.355
  8. Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2014 Aug 14. doi: 10.1007/s00406-014-0520-x. IF=3.355
  9. Wolfsgruber S, Wagner M, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Pantel J, Rienhoff O, Rüther E, Henn F, Wiltfang J, Maier W, Kornhuber J, Jessen F. Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. PLoS One. 2014 Jul 14;9(7):e100812. doi: 10.1371/journal.pone.0100812. (IF 3.534).
  10. Escott-Price V, Bellenguez C, Wang LS, Choi SH, Harold D, Jones L, Holmans P, Gerrish A, Vedernikov A, Richards A, DeStefano AL, Lambert JC, Ibrahim-Verbaas CA, Naj AC, Sims R, Jun G, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Denning N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Schmidt H, Kunkle B, Dunstan ML, Vronskaya M; United Kingdom Brain Expression Consortium, Johnson AD, Ruiz A, Bihoreau MT, Reitz C, Pasquier F, Hollingworth P, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Hernández I, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, George-Hyslop PS, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Garcia FS, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Scarpini E, Bonuccelli U, Mancuso M, Siciliano G, Moebus S, Mecocci P, Zompo MD, Maier W, Hampel H, Pilotto A, Frank-García A, Panza F, Solfrizzi V, Caffarra P, Nacmias B, Perry W, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Haines JL, Lathrop M, Pericak-Vance MA, Launer LJ, Van Broeckhoven C, Farrer LA, van Duijn CM, Ramirez A, Seshadri S, Schellenberg GD, Amouyel P, Williams J. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. PLoS One. 2014 Jun 12;9(6):e94661. doi: 10.1371/journal.pone.0094661. (IF 3.534 ).
  11. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza  LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL.
    Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. IF=21.823
  12. Lista S, Zetterberg H, Dubois B, Blennow K, Hampel H. Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.J Neurol. 2014 Jun;261(6):1234-43. doi: 10.1007/s00415-014-7366-z. IF= 3.841
  13. Kljajevic V, Meyer P, Holzmann C, Dyrba M, Kasper E, Bokde AL, Fellgiebel A, Meindl T, Hampel H, Teipel S; EDSD study group. The ε4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. Alzheimers Dement. 2014 May;10(3):401-4. doi: 10.1016/j.jalz.2013.02.008. IF=17.74
  14. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 2014 May 2. doi:10.1016/j.jalz.2014.02.004. IF=17.472
  15. Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimers Dement. 2014 May;10(3):381-92. doi: 10.1016/j.jalz.2013.04.506. IF=17.472
  16. Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO,  Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D,  Blankenstein MA, Scheltens P, van der Flier WM. The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? Alzheimers Dement. 2014  Apr 7. doi: 10.1016/j.jalz.2013.12.023. (IF 17.472)
  17. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, Li R, Shen Y. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis. 2014;41(3):877-86. doi: 10.3233/JAD-140177. IF= 3.612
  18. Teipel SJ, Grothe MJ, Filippi M, Fellgiebel A, Dyrba M, Frisoni GB, Meindl T, Bokde AL, Hampel H, Klöppel S, Hauenstein K; EDSD study group. Fractional anisotropy changes in Alzheimer's disease depend on the underlying fiber tract architecture: a multiparametric DTI study using joint independent component analysis. J Alzheimers Dis. 2014;41(1):69-83. doi: 10.3233/JAD-131829. IF= 3.612
  19. Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro E Jr, Dos Santos GA, da Silva RE, Mitchell AJ, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Klöppel S, Teipel SJ. Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. J Alzheimers Dis. 2014;40(3):687-700. doi: 10.3233/JAD-132345. IF= 3.612
  20. Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.  Biochem Pharmacol. 2014 Apr 15;88(4):426-49. doi: 10.1016/j.bcp.2013.11.009. IF=4.650
  21. Liu G, Yao L, Liu J, Jiang Y, Ma G; Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium, Chen Z, Zhao B, Li K. Collaborators: Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Chapman J, Russo G, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith A, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Holmans P, O'Donovan M, Owen MJ, Williams J. Cardiovascular disease contributes to Alzheimer's disease: evidence from large-scale genome-wide association studies. Neurobiol Aging. 2014 Apr;35(4):786-92. doi: 10.1016/j.neurobiolaging.2013.10.084. IF=4.853
  22. Morgen K, Ramirez A, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Hampel H, Teipel SJ, Pantel J, Heuser I, Wiltfang J, Rüther E, Kornhuber J, Maier W, Meyer-Lindenberg A. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimers Dement. 2014 Mar 6. doi: 10.1016/j.jalz.2013.11.001. IF=17.472.
  23. Teipel SJ, Grothe MJ, Filippi M, Fellgiebel A, Dyrba M, Frisoni GB, Meindl T,  Bokde AL, Hampel H, Klöppel S, Hauenstein K. Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. J Alzheimers Dis. 2014;41(1):69-83. doi: 10.3233/JAD-131829. (IF 4.174).
  24. Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro Jr E, Dos Santos GA, da Silva RE, Mitchell AJ, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Klöppel S, Teipel SJ. Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. J Alzheimers Dis. 2014;40(3):687-700. doi: 10.3233/JAD-132345. (IF 4.174).
  25. Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. IF=7.833
  26. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013 Dec;45(12):1452-8. doi: 10.1038/ng.2802. IF=29.648
  27. Dubois B, Epelbaum S, Santos A, Di Stefano F, Julian A, Michon A, Sarazin M, Hampel H. Alzheimer disease: from biomarkers to diagnosis. Rev Neurol (Paris). 2013 Oct;169(10):744-51. doi: 10.1016/j.neurol.2013.07.016. IF=0.61
  28. Taverna M, Straub T, Hampel H, Rujescu D, Lichtenthaler SF. A New Sandwich Immunoassay for Detection of the α-Secretase Cleaved, Soluble Amyloid-β Protein Precursor in Cerebrospinal Fluid and Serum. J Alzheimers Dis. 2013;37(4):667-78. doi: 10.3233/JAD-130509. (IF 3.612).
  29. Morgen K, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Hampel H, Teipel SJ, Pantel J, Heuser I, Wiltfang J, Rüther E, Kornhuber J, Maier W, Meyer-Lindenberg A. APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. J Alzheimers Dis. 2013;37(2):389-401. doi: 10.3233/JAD-130326. (IF 3.612).
  30. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007. IF=17.472
  31. Harold D,  Abraham R,  Hollingworth P,  Sims R,  Gerrish A,  Hamshere ML,  Pahwa JS,  Moskvina V,  Dowzell K,  Williams A,  Jones N,  Thomas C,  Stretton A,  Morgan AR,  Lovestone S,  Powell J,  Proitsi P,  Lupton MK,  Brayne C,  Rubinsztein DC,  Gill M,  Lawlor B,  Lynch A,  Morgan K,  Brown KS,  Passmore PA,  Craig D,  McGuinness B,  Todd S,  Holmes C,  Mann D,  Smith AD,  Love S,  Kehoe PG,  Hardy J,  Mead S,  Fox N,  Rossor M,  Collinge J,  Maier W,  Jessen F,  Schürmann B,  Heun R,  van den Bussche H,  Heuser I,  Kornhuber J,  Wiltfang J,  Dichgans M,  Frölich L, Hampel H,  Hüll M,  Rujescu D,  Goate AM,  Kauwe JS,  Cruchaga C,  Nowotny P,  Morris JC,  Mayo K,  Sleegers K,  Bettens K,  Engelborghs S,  De Deyn PP,  Van Broeckhoven C,  Livingston G,  Bass NJ,  Gurling H,  McQuillin A,  Gwilliam R,  Deloukas P,  Al-Chalabi A,  Shaw CE,  Tsolaki M,  Singleton AB,  Guerreiro R,  Mühleisen TW,  Nöthen MM,  Moebus S,  Jöckel KH,  Klopp N,  Wichmann HE,  Carrasquillo MM,  Pankratz VS,  Younkin SG,  Holmans PA,  O'Donovan M,  Owen MJ,  Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2013 May 29;45(6):712. (IF 35.532).
  32. Kljajevic V,  Meyer P,  Holzmann C,  Dyrba M,  Kasper E,  Bokde AL,  Fellgiebel A,  Meindl T, Hampel H,  Teipel S;  EDSD study group. study group. The ε4 genotype of Apolipoprotein E and white matter integrity in Alzheimer’s disease. Alzheimers Dement. 2013 May 21. doi:10.1016/j.jalz.2013.02.008. (IF 17.472).
  33. Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Verhey FR, Winblad B, Wahlund LO, Wilcock G, Visser PJ. Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dement Geriatr Cogn Disord. 2013 May 3;36(1-2):1-19. (IF 2.787).
  34. Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey FR, Aalten P, PhD; Lapuerta P, van de Pol L, van Schijndel R, de Jong R, Barkhof F, Wolz R, Rueckert D, Bocchetta M, Tsolaki M, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, Visser PJ. Measurements             of medial temporal lobe atrophy for prediction of AD in subjects with MCI. Neurobiol Aging. 2013   Mar 26. doi: 10.1016/j.neurobiolaging.2013.02.002 (IF 6.189).
  35. Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H. CSF biomarkers for Alz            heimer's pathology and the effect size of APOE ɛ4. Mol Psychiatry. 2014;19(2):148-9. (IF 14.897). 
  36. Vermeiren AP, Bosma H, Visser PJ, Zeegers MP, Graff C, Ewers M, Frisoni GB, Frölich L,             Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili FM, Olde Rikkert M, Rigaud AS, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund LO, Vellas B, Wilcock G, Elias-            Sonnenschein LS, Verhey FR. The Association Between APOE ε4 and Alzheimer-type Dementia       among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA    Study. J Alzheimers Dis. 2013 Feb 4 (IF 4.261).
  37. Martin Dyrba, Michael Ewers, Martin Wegrzyn, Ingo Kilimann, Claudia Plant, Annahita Oswald, Thomas Meindl, Michela Pievani, Arun L.W. Bokde, Andreas Fellgiebel, Massimo Filippi, Harald Hampel, Stefan Klöppel, Karlheinz Hauenstein, Thomas Kirste, Stefan J. Teipel. Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data PLoS One. 2013 May 31;8(5):e64925. (IF 4.411).
  38. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC,             AmouyelP, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J; Alzheimer Genetic Analysis Group. Collaborators: Guerreiro R, Wojtas A, Bras J, Carasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Lupton MK, Ryten M, Brown K, Lowe J, Ridge PG, Hammer MB, Wakutani Y, Hazrati L, Proitsi P, Newhouse S, Lohmann E, Erginel-Unaltuna N, Medway C, Hanagasi H, Troakes C, Gurvit H, Bilgic B, Al-Sarraj S, Benitez B, Cooper B, Carrell D, Emre M, Zou F, Ma L, Murray M, Dickson D, Younkin S, Petersen RC, Corcoran CD, Cai Y, Oliveira C, Ribeiro MH, Santana I, Tschanz JT, Gibbs J, Norton MC, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Munger RG, Mann DM, Pickering-Brown S, Lovestone S, Beck J, Mead S, Collinge J, Parsons L, Pocock J, Morris JC, Revesz T, Lashley T, Fox NC, Rossor MN, Grenier-Boley B, Bellenguez C, Moskvina V, Sims R, Harold D, Williams J, Lambert JC, Amouyel P, Graff-Radford N, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Gerrish A, Chapman J, Abraham R, Hollingworth P, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Williams K, Thomas S, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Passmore P, Craig D, McGuinness B, Johnston JA, Todd S, Holmes C, Smith A, Love S, Kehoe PG, Maier W, Jessen F,  Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Nowotny P, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Nöthen MM, Holmans P, O'Donovan M, Owen MJ, Zelenika D, Epelbaum J, Dartigues JF, Tzourio C, Berr C, Boland A, Campion D, Alpérovitch A, Lathrop M, Smith C, Trabzuni D, Walker R, Weale M. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013 Jan 10;368(2):117-127. doi: 10.1056/NEJMoa1211851. (IF 53.298).
  39. Buschert VC, Giegling I, Teipel SJ, Jolk S, Hampel H, Rujescu D, Buerger K. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. J Clin Psychiatry. 2012 Dec;73(12):e1492-1498. (IF 5.812)
  40. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S,             Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K,     Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Arfan Ikram M, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. A Coding Variant in TREM2 Confers Risk of Alzheimer’s Disease. N Engl J Med. 2012. DOI: 10.1056/NEJMoa1211103. (IF 53.298).
  41. Vos SJB, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni G, Froelich L, Nobili F, van der Flier WM, Blennow K, Wolz R, Scheltens P, Visser PJ. Prediction of Alzheimer’s disease in subjects with amnestic and non-amnestic MCI.             Neurology. 2012 Accepted. (IF 8.312).
  42. Bede P, Bokde A, Elamin M, Byrne S, McLaughlin RL, Jordan N, Hampel H, Gallagher L, Lynch C, Fagan AJ, Pender N, Hardiman O. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical             focality. J Neurol Neurosurg Psychiatry. 2012 Oct 20. (IF 4.764).
  43. van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F,             Rueckert D, Wolz R, Verhey F, Visser PJ. Injury markers predict time to dementia in subjects with             MCI and amyloid pathology. Neurology. 2012 Sep 26. (IF 8.312).
  44. Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, Rikkert MO, Verbeek MM, Spiru L, Blennow K, Trojanowski JQ, Shaw LM, Visser PJ, the Alzheimer’s Disease Neuroimaging Initiative and DESCRIPA Investigators. Anxiety is related to Alzheimer’s disease markers in cerebrospinal fluid of subjects with mild cognitive impairment. Psychol Med. 2012 Sep 7:1-10. (IF 6.159).
  45. Hamilton G, Harris SE, Davies G, Liewald DC, Tenesa A, Payton A, Horan MA, Ollier WE, Pendleton N; Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium, Starr    JM, Porteous D, Deary IJ. Collaborators: Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Chapman J, Russo G, Hamshere M, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown K, Passmore P, Craig D, McGuinness B, Todd S, Johnston J, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J,             Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Heun R, Kölsch H, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate A, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Holmans P, O'Donovan M, Owen MJ, Wil            liams J. The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk. Am J Med Genet B Neuropsychiatr Genet. 2012 Sep;159B(6):696-709. (IF 3.705).
  46. Alves GS, Karakaya T, Fußer F, Kordulla M, O’Dwyer L, Christll J, Magerkurth J, Oertel-Knöchel V, Knöchel C, Prvulovic D, Jurcoane A, Laks J, Engelhardt E, Hampel H, Pantel J. Association of microstructural white matter abnormalities with cognitive dysfunction in geriatric patients with major depression. Psychiat Res. 2012 Aug;203(2-3):194-200. (IF 2.064).
  47. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012 Aug;6(4):419-430. (IF 2.63).
  48. Teipel SJ, Wegrzyn M, Meindl T, Frisoni G, Bokde A, Fellgiebel A, Filippi M, Hampel H, Klöppel S, Hauenstein K, Ewers M; and the EDSD study group. Anatomical MRI and DTI in the diagnosis of Alzheimer’s disease: a European Multicenter Study. J Alzheimers Dis. 2012;31 Suppl 3:S33-S47. (IF 3.745).
  49. Knöchel C, O'Dwyer L, Alves G, Reinke B, Magerkurth J, Rotarska-Jagiela A, Prvulovic D, Hampel H, Linden DE, Oertel-Knöchel V. Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. Schizophr Res. 2012 Sep;140(1-3):129-35. (IF 4.748)
  50. Shi H, Belbin O, Medway C, Brown K, Kalsheker N, Carrasquillo M, Proitsi P, Powell J, Lovestone S, Goate A, Younkin S, Passmore P; Genetic and Environmental Risk for Alzheimer's Disease Consortium, Morgan K; Alzheimer's Research UK Consortium. Collaborators: Harold D, Hampel H et al. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging. 2012 Aug;33(8):1849.e5-18. (IF 6.189).
  51. Hamilton G, Killick R; Genetic and Environmental Risk for Alzheimer's Disease Consortium; Translational Genomics Research Institute Consortium, Lambert JC, Amouyel P; European Alzheimer Disease Initiative, Carrasquillo MM, Pankratz VS, Graff-Radford NR, Dickson DW, Petersen RC, Younkin SG, Powell JF, Wade-Martins R. Collaborators: Harold D, Hampel H et al. Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus. Neurobiol Aging. 2012 Aug;33(8):1848.e1-13. (IF 6.189). 
  52. Hummel D, Rudolf AK, Brandi ML, Untch KH, Grabhorn R, Hampel H, Mohr HM.  Neural adaptation to thin and fat bodies in the fusiform body area and middle occipital gyrus: a fMRI adaptation study. Hum Brain Mapp. 2012 Jul 17. [Epub ahead of print]. (IF 5.88).
  53. Soldner J, Meindl T, Koch W, Bokde ALW, Reiser MF, Möller HJ, Bürger K, Hampel H, Teipel SJ. Strukturelle und funktionelle neuronale Konnektivität bei der Alzheimer-Krankheit. Eine             kombinierte DTI- und fMRT-Studie. [Structural and functional neuronal connectivity in Alzheimer's disease: a combined DTI and fMRI study]. Nervenarzt. 2012 Jul;83(7):878-887. (IF 0.681).
  54. Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative. Collaborators: A S, Abdi H, Hampel H et al. Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol Ag     ing. 2012 Jun;33(6):1124.e31-41. (IF 6.189).
  55. Hudson G, Sims R, Harold D, Chapman J, Hollingworth P, Gerrish A, Russo G, Hamshere M, Moskvina V, Jones N, Thomas C, Stretton A, Holmans PA, O'Donovan MC, Owen MJ, Williams J, Chinnery PF; GERAD1 Consortium. Collaborators: Harold D, Hampel H et al. No consistent evi            dence for association between mtDNA variants and Alzheimer disease. Neurology. 2012 Apr     3;78(14):1038-42. (IF 8.312).
  56. Fehlbaum-Beurdeley P, Sol O, Désiré L,  Touchon J, Dantoine T, Vercelletto M, Gabelle A, Jarrige AC, Haddad R, Lemarié JC, Higgs BW, Zhou W, Hampel H, Einstein R, Vellas B, Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2012 Jan 1;32(1):169-81. (IF 3.745).
  57. Oertel-Knöchel V, Knöchel C, Matura S, Rotarska-Jagiela A, Magerkurth J, Prvulovic D, Haenschel C, Hampel H, Linden DE. Cortical-basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. Schizophr Res. 2012 Jul;138(2-3):120-127 (IF 4.374)
  58. Oertel-Knöchel V, Reinke B, Hornung A, Knöchel C, Matura S, Knopf M, Prvulovic D, O'Dwyer L, Lindner M, Rau A, Hampel H, Haenschel C, Linden DEJ. Patterns of autobiographical memory in bipolar disorder examined by psychometric and functional neuroimaging methods. J Nerv Ment Dis. 2012 Apr;200(4):296-304. (IF 1.796).
  59. Vellas B, Grundman M, Andrieu S, Abushakra S, Bain LJ, Bateman R, Black R, Carrillo M, Donohue M, Hampel H, Mintun M, Morris J, Petersen R, Thomas R, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P; and Task Force Participants. Alzheimer’s disease therapeutic trials: EU/US Task Force Report on Recruitment, Retention, and Methodology. J Nutr Health Aging. 2012 Apr;16(4):339-45. (IF 2.484).
  60. Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, Hampel H, Kastler J, Senn H. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One. 2012. 7(2):e31501.(IF 4.411)
  61. Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, Sims R, Abraham R, Hollingworth P, Chapman J, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Kölsch H, Heun R, Schürmann B, Bussche HV, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Davies G, Harris SE, Starr JM, Deary IJ, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Jones L, Holmans PA, O'Donovan MC, Owen MJ, Williams J. The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis. 2012; 28(2):377-87. Epub 2011 Oct 25. (IF 4.261)
  62. Jacobs HI, Visser PJ, Van Boxtel MP, Frisoni GB, Tsolaki M, Papapostolou P, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, van de Pol L, Scheltens P, Tan FE, Jolles J, Verhey FR. The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiol Aging. 2012; 33(1):201.e1-8. Epub 2010 Aug 23. (IF 6.634)
  63. Knöchel C, Oertel-Knöchel V, Schönmeyer R, Rotarska-Jagiela A, van de Ven V, Prvulovic D, Haenschel C, Uhlhaas P, Pantel J, Hampel H, Linden DE. Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. Neuroimage. 2012; 59(2):926-34. Epub 2011 Sep 26. (IF 5.932)
  64. Koch W, Teipel S, Mueller S, Benninghoff J, Wagner M, Bokde AL, Hampel H, Coates U, Reiser M, Meindl T. Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiol Aging. 2012; 33(3):466-78. Epub 2010 Jun 10. (IF 6.634)
  65. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schroeder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jönhagen M, Minthon L, Winblad B, Blennow K, Zetterberg H. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012; 78(7):468-76. Epub Feb 1. (IF 8.017)
  66. Oertel-Knöchel V, Knöchel C, Rotarska-Jagiela A, Reinke B, Prvulovic D, Haenschel C, Hampel H, Linden DEJ. Association between psychotic symptoms and cortical thickness reduction across the schizophrenia spectrum. Cereb Cortex. 2012 Jan 30. [Epub ahead of print] (IF 6.844)
  67. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L’Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging. 2012 Oct;33(10):2272-81. Epub 2012 Jan 20. (IF 6.634).
  68. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frölich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang  J. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012; 78(6):379-86. Epub 2012 Jan 11. (IF 8.017).
  69. Wei X, Roettger Y, Tan B, He Y, Dodel R, Hampel H, Wei G, Haney J, Gu H, Johnstone BH, Far   low MR, Du Y. Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. J Biol Chem. 2012 Apr 13;287(16):12858-66 (IF 5.328).
  70. Bartley M, Bokde AL, Ewers M, Faluyi YO, Tobin WO, Snow A, Connolly J, Delaney C, Coughlan T, Collins DR, Hampel H, O'Neill D. Subjective memory complaints in community dwelling healthy older people: the influence of brain and psychopathology. Int J Geriatr Psych. 2011 Sep 27. [Epub ahead of print] (IF 2.029).
  71. Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, Möller HJ, Hampel H, Buerger K. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer’s disease: A pilot study. J Alzheimers Dis. 2011; 25(4):679-94. Epub 2011 Apr 11. (IF 4.261).
  72. Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer’s disease. J Alzheimers Dis. 2011; 25(4):695-706. Epub 2011 Apr 15. (IF 4.261).
  73. Förster S, Buschert VC, Teipel SJ, Friese U, Buchholz HG, Drzezga A, Hampel H, Bartenstein P, Buerger K. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer's disease. J Alzheimers Dis. 2011; 26(Suppl 3):337-48. (IF 4.261).
  74. Frings L, Klöppel S, Teipel S, Peters O, Frölich L, Pantel J, Schröder J, Gertz HJ, Arlt S, Heuser I, Kornhuber J, Wiltfang J, Maier W, Jessen F, Hampel H, Hüll M. Left anterior temporal lobe sustains naming in Alzheimer’s dementia and mild cognitive impairment. Curr Alzheimer Res. 2011; 8(8):893-901. Epub 2011 May 18. (IF 4.953).
  75. Frodl T, Scheuerecker J, Schoepf V, Linn J, Koutsouleris N, Bokde AL, Hampel H, Moeller HJ, Brueckmann H, Wiesmann M, Meisenzahl E. Different effects of mirtazapine and venlafaxine on brain activation: an open fMRI study. J Clin Psychiat. 2011; 72(4):448-57. Epub 2010 Sep 21. (IF 5.023).
  76. Fußer F, Linden DE, Rahm B, Hampel H, Haenschel C, Mayer JS. Common capacity-limited neural mechanisms of selective attention and spatial working memory encoding. Eur J Neurosci. 2011; 34(5):827-38. Epub 2011 Jul 22. (IF 3.658).
  77. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ERLC, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Gallacher J, Rujescu D, Giegling I, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, the Alzheimer’s Disease Neuroimaging Initiative, van Duijn CM, Breteler MMB, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, CHARGEconsortium, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alpérovitch A, Lathrop M, EADI1 consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snædal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O’Donovan M, Amouyel P, Williams J.  Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011; 43(5):429-35. (IF 36.377).
  78. Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker for clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement. 2011; 7(4):474-85.e4. (IF 5.902).
  79. Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y.,Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener. 2011; 6(1):69. (IF 5.361).
  80. Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative, Goate AM; Collaborators: Hampel H et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer’s disease. PLoS One. 2011; Feb 9;6(2):e15918. (IF 4.411).
  81. Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P. CALHM1 P86L polymorphism modulates CSF Ab levels in cognitively healthy individuals at risk for Alzheimer’s disease. Mol Med. 2011; 17(9-10):974-9. Epub 2011 May 24. (IF 5.908).
  82. Likitjaroen Y, Meindl T, Friese, U, Wagner M, Buerger K, Hampel H, Teipel SJ. Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month ranomized, placebo-controlled, double-blinded study. Eur Arch Psychiatry Clin Neurosci. 2011 Aug 5. [Epub ahead of print] (IF 3.637)
  83. Mattsson N, Andreasson U, Persson S, Albert M, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, O Forlenza, Frisoni GB, Galasko D, Galimberti D, Hampel H et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011; 7(4):386-95.e6. (IF 5.902).
  84. McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM; Alzheimer’s Disease Neuroimaging Initiative. [Collaborators (1091): Saradha A … Hampel H et al.] Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology. 2011; 259(3):834-43. Epub 2011 Apr 6. (IF 6.066).
  85. Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund LO, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FR, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord. 2011; 32(2):135-42. Epub 2011 Sep 22. (IF 2.455).
  86. Olsson B, Zetterberg H, Hampel H, Blennow K. Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol. 2011; 95(4):520-34. Epub 2011 Apr 16. (IF 9.966).
  87. Schneider B, Grebner K, Schnabel A, Hampel H, Georgi K, Seidler A. Impact of employment status and work-related factors on risk of completed suicide A case-control psychological autopsy study. Psychiatry Res. 2011; 190(2-3):265-70. Epub 2011 Sep 2. (IF 2.803).
  88. Sikkes SA, Visser PJ, Knol DL, de Lange-de Klerk ES, Tsolaki M, Frisoni GB, Nobili F, Spiru L, Rigaud AS, Frölich L, Rikkert MO, Soininen H, Touchon J, Wilcock G, Boada M, Hampel H, Bullock R, Vellas B, Pijnenburg YAL, Scheltens P, Verhey FR, Uitdehaag BM. Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the development of screening guidelines and diagnostic criteria for predementia Alzheimer’s disease study. J Am Geriatr Soc. 2011; 59(12):2273-81. (IF 3.913).
  89. Soldner J, Meindl T, Koch W, Bokde ALW, Reiser MF, Möller HJ, Bürger K, Hampel H, Teipel SJ. Strukturelle und funktionelle neuronale Konnektivität bei der Alzheimer-Krankheit. Eine kombinierte DTI- und fMRT-Studie. [Structural and functional neuronal connectivity in Alzheimer's disease: A combined DTI and fMRI study]. Nervenarzt. 2011 Jun 30. [Epub ahead of print] (IF 0.729)
  90. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol. 2011; 95(4):547-56. Epub 2011 May 12. (IF 9.966).
  91. Teipel SJ, Peters O, Heuser I, Jessen F, Maier W, Froelich L, Arlt S, Hüll M, Gertz HJ, Kornhuber J, Wiltfang J, Thome J, Rienhoff O, Meindl T, Hampel H, Grothe M. Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. World J Biol Psychia. 2011; 12(S1):109-13. (IF 2.048).
  92. Yakushev I, Müller MJ, Buchholz HG, Lang U, Rossmann H, Hampel H, Schreckenberger M, Fellgiebel A. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer’s disease. Curr Alzheimer Res. 2012 Feb;9(2):241-7 [Epub ahead of print] (IF 4.953).
  93. Bergfield KL, Hanson KD, Chen K, Teipel SJ, Hampel H, Rapoport SI, Moeller JR, Alexander GE. Age-related networks of regional covariance in MRI gray matter: reproducible multivariate patterns in healthy aging. Neuroimage. 2010; 49(2):1750-9. (IF 5.739).
  94. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Beck CR Jr, Weiner M, DeCarli C, Alzheimer’s Disease Neuroimaging Initiative. Collaborators: Abdi H, Hampel H et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol. 2010; 67(11):1370-8. (IF 6.312).
  95. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010; 9(11):1118-27. (IF 18.126).
  96. Förster S, Teipel SJ, Zach C, Rominger A, Cumming P, Fougere CL, Yakushev I, Haslbeck M, Hampel H, Bartenstein P, Bürger K. FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer’s disease. J Psychiatr Res. 2010; 44(7):462-9. (IF 3.723).
  97. Förster S, Vaitl A, Teipel SJ, Yakushev I, Mustafa M, la Fougère C, Rominger A, Cumming P, Bartenstein P, Hampel H, Hummel T, Buerger K, Hundt W, Steinbach S. Functional representation of olfactory impairment in early Alzheimer’s disease. J Alzheimers Dis. 2010; 22(2):581-91. (IF 3.832).
  98. Friese U, Meindl T, Herpertz S, Reiser MF, Hampel H, Teipel SJ. Diagnostic utility of novel MRI-based biomarkers for Alzheimer's disease: Diffusion tensor imaging and deformation-based morphometry. J Alzheimers Dis. 2010; 20(2):477-90.(IF 3.832).
  99. Frodl T, Bokde AL, Scheuerecker J, Lisiecka D, Schoepf V, Hampel H, Moeller HJ, Brückmann H, Wiesmann M, Meisenzahl E. Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. Biol Psychiat. 2010; 67(2):161-7. (IF 8.926).
  100. Frodl T, Stauber J, Schaaff N, Koutsouleris N, Scheuerecker J, Ewers M, Omerovic M, Opgen-Rhein M, Hampel H, Reiser M, Moeller HJ, Meisenzahl E. Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers. Acta Psychiat Scand. 2010; 121(2):111-8. (IF 3.733).
  101. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O’Donovan MC, Owen MJ, Williams J. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS one. 2010; Nov 15;5(11):e13950. (IF 4.351)
  102. Koch W, Teipel SJ, Mueller S, Buerger K, Bokde A, Hampel H, Coates U, Reiser M, Meindl T. Effects of aging on default mode network activity in resting state fMRI: Does the method of analysis matter? Neuroimage. 2010; 51(1):280-7. (IF 5.739)
  103. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Buerger K, Hampel H, Froelich L, Wolf S, Prinz B, Jahn H, Luckhaus CH, Pernesczky R, Huell M, Schroeder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Koelsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatr. 2010; 15(2):138-45. (IF 15.049)
  104. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Buerger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J. Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp Neurol. 2010; 223(2):366-70. (IF 3.914)
  105. Luckhaus C, Cohnen M, Flüss MO, Jänner M, Grass-Kapanke B, Teipel SJ, Grothe M, Hampel H, Peters O, Kornhuber J, Maier W, Supprian T, Gaebel W, Mödder U, Wittsack HJ. The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiat Res-Neuroim. 2010; 183(1):44-51. (IF 3.435)
  106. Luckhaus C, Jaenner M, Cohnen M, Fluess MO, Teipel SJ, Grothe M, Hampel H, Kornhuber J, Ruether E, Supprian T, Gaebel W, Moedder U, Wittsack HJ. A novel MRI-biomarker of Alzheimer’s disease composed of regional brain volume and perfusion variables. Eur J Neurol. 2010; 17(12):1437-44.(IF 2.51)
  107. Meisenzahl EM, Seifert D, Bottlender R, Teipel S, Zetzsche T, Jäger M, Koutsouleris N, Schmitt G, Scheuerecker J, Burgermeister B, Hampel H, Rupprecht T, Born C, Reiser M, Möller HJ, Frodl T. Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. Eur Arch Psy Clin N. 2010; 260(2):127-37. (IF 2.747)
  108. Plant C, Teipel SJ, Oswald A, Böhm C, Meindl T, Mourao-Miranda J, Bokde AW, Hampel H, Ewers M. Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer’s disease. Neuroimage. 2010; 50(1):162-74. (IF 5.739)
  109. Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener. 2010; 5:2. (IF 5.091)
  110. Benninghoff J, Möller HJ, Hampel H, Vescovi AL. The problem of being a paradigm: the emergence of neural stem cells as example for “Kuhnian” revolution in biology or misconception of the scientific community? Poiesis and Praxis. 2009; 6(1):3-11. (IF -)
  111. Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, Wiltfang J; KND-Study Group, Heuser I, Maier W, Luckhaus C, Rüther E, Hüll M, Jahn H, Gertz HJ, Frölich L, Hampel H, Pernetzki R. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging. 2009;13(3):205-8. (IF 2.321)
  112. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere M, Singh Pahwa J, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schuermann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Froelich L, Hampel H, Huell M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn P, van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muehleisen TW, Noethen MM, Moebus S, Joeckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O’Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009; 41(10):1088-93. (IF 30.259)
  113. Kornhuber J, ,Schmidtke K, Frölich L, Perneczky R, Wolf S, Hampel H, Jessen F, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Pantel J, Rienhoff O, Seuchter SA, Rüther E, Henn F, Maier W, Wiltfang J. Early and differential diagnosis of dementia and mild cognitive impairment: Design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn. 2009; 27(5):404-17. (IF 3.142)
  114. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroeder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Eriksdotter Jönhagen M, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA-J Am Med Assoc. 2009; 302(4):385-93. (IF 31.718)
  115. van de Pol L, Verhey F, Frisoni GB, Tsolaki M, Papapostolou P, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, Knol DL, Barkof F, Scheltens P, Visser PJ. White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. J Neurol Neurosur Ps. 2009; 80(10):1069-74. (IF 4.622)
  116. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem. 2009; 46(3):235-40. (IF 1.788)
  117. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Buerger K, Pirttila T, Soininen H, Olde Rikkert M, Verbeek M, Spiru L, Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. (IF 14.270)
  118. Wei X, Du Z, Zhao L, Feng D, Wei G, He Y, Tan J, Lee WH, Hampel H, Dodel R, Johnstone BH, March KL, Farlow MR, Du Y. IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells. 2009; 27(2):478-88. (IF 7.741)
  119. Frisoni GB, Henneman WJP, Weiner MW, Scheltens P, Vellas B, Reynish E, Hudecova J, Hampel H, Buerger K, Blennow K, Waldemar G, Johannsen P, Wahlund LO, Zito G, Rossini PM, Winblad B, Barkhof F, Alzheimer’s Disease Neuroimaging Initiative. The pilot European Alzheimer’s Disease Neuroimaging Initiative of the European Alzheimer’s Disease Consortium. Alzheimer’s & Dementia. 2008; 4(4):255-64. (IF -)
  120. Juckel G, Clotz F, Frodl T, Kawohl W, Hampel H, Pogarell O, Hegerl U. Diagnostic usefulness of cognitive auditory event-related p300 subcomponents in patients with Alzheimer’s disease? J Clin Neurophysiol. 2008; 25(3):147-52. (IF 1.740)
  121. Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, Evans AC. Automated cortical thickness measurements from MRI can accurately separate Alzheimer’s patients from normal elderly controls. Neurobiol Aging. 2008; 29(1):23-30. (IF 5.959)
  122. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging. 2008; 29(6):812-8. (IF 5.959)
  123. Lorenzl S, Bürger K, Hampel H, Beal MF. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr. 2008; 20(1):67-76. (IF 2.098)
  124. Visser PJ, Verhey F, Boada M, Bullock R, De Deyn PP, Frisoni GB, Frölich L, Hampel H, Jolles J, Jones R, Minthon L, Nobili F, Olde Rikkert M, Ousset PJ, Rigaud AS, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Wahlund LO, Wilcock G, Winblad B. Development of screening guidelines and clinical criteria for predementia Alzheimer’s disease – the DESCRIPA study. Neuroepidemiology. 2008; 30(4):254-65. (IF 1.737)
  125. Leinsinger G, Born C, Meindl T, Bokde ALW, Britsch S, Lopez-Bayo P, Teipel SJ, Möller HJ, Hampel H, Reiser MF. Age-dependent differences in human brain activity using a face- and location-matching task: an fMRI-Study. Dement Geriatr Cogn. 2007; 24(4):235-46. (IF 2.641)
  126. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, Schoenberg SO. White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion tensor MR imaging and parallel imaging techniques. Radiology. 2007; 243(2):483-92. (IF 5.561)
  127. Sydykova D, Stahl R, Dietrich O, Ewers M, Reiser M, Schoenberg O, Moeller H-J, Hampel H, Teipel SJ. Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer’s disease: a diffusion tensor imaging and voxel-based morphometry study. Cerebr Cortex. 2007; 17(10):2276-82. (IF 6.519)
  128. Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease. Eur Arch Psy Clin N. 2007; 257(6):330-6. (IF 2.809)
  129. Wei X, Chen X, Fontanilla C, Zhao L, Liang Z, Dodel R, Hampel H, Farlow M, Du Y. C/T conversion alters interleukin-1A promoter function in a human astrocyte cell line, Life Sci. 2007; 80(12):1152-6. (IF 2.257)
  130. Wiltfang J, Esselmann H, Bibl M, Huell M, Hampel H, Kessler H, Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem. 2007; 101(4):1053-9. (IF 4.451)
  131. Yamamori H, Khatoon S, Grundke-Iqbal I, Blennow K, Ewers M, Hampel H, Iqbal K. Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neurosci Lett. 2007; 418(2):186-9. (IF 2.085)
  132. Zhong Z, Ewers M, Teipel SJ, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiat. 2007; 64(6):718-26. (IF 15.976)
  133. Alexander G, Chen K, Merkley TL, Reiman EM, Caselli RJ, Aschenbrenner M, Santerre-Lemmon L, Lewis D, Pietrini P, Teipel SJ, Hampel H, Rapoport SI, Moeller JR. Regional network of magnetic resonance imaging gray matter volume in healthy aging. Neuroreport. 2006; 17(10):951-6. (IF 2.137)
  134. Bickel H, Bürger K, Hampel H, Schreiber Y, Sonntag A, Wiegele B, Förstl H, Kurz A. Präsenile Demenzen in Gedächtnisambulanzen – Konsultationsinzidenz und Krankheitscharakteristika. [Presenile dementia in memory clinics – incidence rates and clinical features]. Nervenarzt. 2006; 77(9):1079-85. (IF 0.711)
  135. DeLeon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006; 27(3):394-401. (IF 5.599)
  136. Glatz DC, Rujescu D, Tang Y, Berendt FJ, Hartmann AM, Faltraco F, Rosenberg C, Hulette C, Jellinger K, Hampel H, Riederer P, Möller HJ, Andreadis A, Henkel K, Stamm S. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem. 2006; 96(3):635-44. (IF 4.260)
  137. Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, Schindler R, AWARE Study Group. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs. 2006; 20(4):311-25. (IF 4.210)
  138. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhamer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schönknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Wurster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett. 2006; 409(1):1-4. (IF 2.092)
  139. Ma Z, Wei X, Fontanilla C, Noelker C, Dodel R, Hampel H, Du Y. Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. Life Sci. 2006; 79(13):1307-11. (IF 2.389)
  140. Stuebner S, Omerovic M, Krauseneck T, Hampel H, Grohmann R. Metronomsyndrom unter Kombinationsbehandlung mit Prothipendyl und Antidementiva. Psychopharmakotherap. 2006; 13(2):70-1. (IF 0.190)
  141. Träber F, Block W, Freymann N, Gür O, Kucinski T, Hammen T, Ende G, Pilatus U, Hampel H, Schild HH, Heun R, Jessen F. A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. Eur Radiol. 2006; 16(5):1096-103. (IF 2.554)
  142. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Bürger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Bläser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E. Analytical performance and clinical utility of INNOTEST PHOSPHO-TAU 181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006; 44(12):1472-80. (IF 1.725)
  143. Wermke M, Teipel S, Fuchsberger T, Kretzschmar H, Westner I, Schröder M, Hampel H, Drzezga A. Frontal diaschisis in a German case of fatal familial insomnia. J Neurol. 2006; 253(11):1510-2. (IF 2.984)
  144. Johansson A, Zetterberg H, Hampel H, Buerger K, Prince J, Minthon L, Wahlund LO, Blennow K. Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer’s disease. Dement Geriatr Cogn. 2005; 20:367-74. (IF 2.603)
  145. Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cerebr Cortex. 2005; 15(7):995-1001. (IF 6.187)
  146. Mourão-Miranda J, Bokde ALW, Born C, Hampel H, Stetter M. Classifying brain states and determining the discriminating activation patterns: support vector machine on functional MRI data. Neuroimage. 2005; 28:980-95. (IF 5.288)
  147. Selle H, Lamerz J, Bürger K, Dessauer A, Hager K, Hampel H, Karl J, Kellmann M, Lannfelt L, Louhija J, Riepe M, Rollinger W, Tumani H, Schrader M, Zucht HD. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb Chem High T Scr. 2005; 8(8):801-6. (IF 2.518)
  148. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against ß-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosur Ps. 2004; 75(10):1472-4. (IF 3.110)
  149. Li R, Yang L, Lindholm K, Konishi Y, Yue X, Hampel H, Zhang D, Shen Y. TNF death receptor signaling cascade is required for amyloid-beta protein induced neuron death. J Neurosci. 2004; 24(7):1760-71. (IF 7.907)
  150. Wei X, Zhao L, Ma Z, Holtzman DM, Yan C, Dodel R, Hampel H, Oertel W, Farlow MR, Du Y. Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain. 2004; 127(Pt12):2629-35. (IF 8.201)
  151. Bagli M, Papassotiropoulos P, Hampel H, Becker K, Jessen F, Bürger K, Ptok U, Rao ML, Möller HJ, Maier W, Heun R. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer’s disease, Eur Arch Psy Clin N. 2003; 253:44-8. (IF 2.305)
  152. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M.Human anti-abeta-amyloid antibodies block abeta-amyloid fibril formation and prevent abeta-amyloid-induced neurotoxicity. Brain.2003; 126(9):1935-9. (IF 7.967)
  153. Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Müller-Thomsen T, Oertel W, Viennarich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Treatment with the selective muscarinergic M1 agonist talsaclidine decreases CSF levels of Ab42  in patients with Alzheimer's disease, Amyloid, 2003; 10(1):1-6. (IF 1.579)
  154. Konishi Y, Beach T, Sue LI, Hampel H, Lindholm K, Shen Y. The temporal localization of frame-shifted ubiquitin-B and amyloid precursor protein, and complement proteins in the brain of non-demented control patients with increasing Alzheimer’s disease pathology. Neurosci Lett. 2003; 48(1):46-50. (IF 1.967)
  155. Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Möller HJ, Hampel H, Davidsson P, Blennow K. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol. 2003; 183(1):74-80. (IF 5.005)
  156. Schönknecht P, Pantel J, Hunt A, Volkmann M, Buerger K, Hampel H, Schröder J. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer’s disease, Neurosci Lett. 2003; 339(2):85-7. (IF 1.967)
  157. Schröter A, Mergl R, Bürger K, Hampel H, Möller HJ, Hegerl U. Kinematic analysis of handwriting movements in patients with Alzheimer's disease, mild cognitive impairment, depression and healthy subjects. Dement Geriatr Cogn. 2003; 15(3):132-42. (IF 2.445)
  158. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, Schoenberg SO. Diffusion Tensor Imaging zur Erfassung axonaler Degeneration bei Morbus Alzheimer. [Assessment of axonal degeneration on Alzheimer’s disease with diffusion tensor MRI]. Radiologe. 2003; 43(7): 566-75. (IF 0.626)
  159. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol. 2003; 54(2):263-7. (IF 7.717)
  160. Gao F, Bales KR, Dodel RC, Liu J, Chen X, Hampel H, Farlow MR, Paul SM, Du Y. NF-kappa-b mediates IL-1beta-induced synthesis/release of alpha-2-macroglobulin in human glial cell line. Brain Res Mol Brain Res. 2002; 105:108-14. (IF 2.309)
  161. Heine G, Zucht HD, Schuhmann MU, Bürger K, Jürgens M, Zumkeller M, Schneekloth CG, Hampel H, Schulz-Knappe P, Selle H. High-resolution peptide mapping of cerebrospinal fluid: A novel concept for diagnostics and research in central nervous system diseases. J Chromatogr B. 2002; 25/782(1-2):353-61. (IF 1.913)
  162. Padberg F, Schüle C, Zwanzger P, Baghai T, Ella R, Mikhaiel P, Hampel H, Möller HJ, Rupprecht R. Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. J Psychiatr Res. 2002;36(3):131-5. (IF 2.862)
  163. Padberg F, Zwanzger P, Keck ME, Kathmann N, Mikhaiel P, Ella R, Rupprecht P, Thoma H, Hampel H, Toschi N, Möller HJ. Repetitive transcranial magnetic stimulation (RTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacol. 2002; 27(4):638. (IF 4.497)
  164. Du Y, Dodel R, Hampel H, Bürger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel WH, Farlow M, Paul S. Reduced levels of amyloid-b peptide antibody in Alzheimer’s disease. Neurology. 2001; 57:801-5. (IF 5.212)
  165. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Bürger K, Wiltfang J, Otto M, Kretzschmar H, Möller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001; 50(2):150-6. (IF 8.481)
  166. Lue L, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy G, Brachova L, Yan SD, Walker D, Shen Y, Rogers J. Inflammatory repertoire of Alzheimer’s disease and non-demented elderly microglia in vitro. Glia. 2001; 35(1):72-9. (IF 4.193)
  167. Padberg F, Juckel G, Präßl A, Zwanzger P, Mavrogiorgou P, Hegerl U, Hampel H, Möller HJ. Prefrontal cortex modulation of mood and emotionally induced facial expressions: a transcranial magnetic stimulation study. J Neuropsych Clin N. 2001; 13(2):206-12. (IF 1.632)
  168. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, Blennow K, Arai H, De Deyn PP, Galasko D, Hampel H, Parnetti L, Riemenschneider M, Sindic CJM. CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Neurol Sci. 2001; 22:77-8. (IF 0.380)
  169. Zill P, Engel R, Hampel H, Behrens S, Bürger K, Padberg F, Stübner S, Möller HJ, Ackenheil M, Bondy B. Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. Eur Arch Psy Clin N. 2001; 251(1):24-8. (IF 1.817)
  170. Kahle P, Teipel SJ, Hampel H, Murphy GM Jr. Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology. 2000; 55:1068-9. (IF 4.781)
  171. Gallinat J, Boetsch T, Padberg F, Hampel H, Herrmann WM, Hegerl U. Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature. Pharmacopsychiatry. 2000; 33:169-73. (IF 2.681)
  172. Hofman M, Seifritz E, Kräuchi K, Hock C, Hampel H, Neugebauer A, Müller-Spahn F. Alzheimer’s disease, depression and normal ageing: merit of simple psychomotor and visuospatial tasks. Int J Geriatr Psych. 2000; 15(1):31-9. (IF 1.495)
  173. Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Möller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GM. Combined Assessment of Tau and Neuronal Thread Protein Alzheimer’s diasease Cerebrospinal Fluid, Neurology. 2000; 54(7):1498-504. (IF 4.781).
  174. Stübner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H, Möller HJ, Rüther E. Pisa syndrome (Pleurothotonus) – Report of a multicentre drug safety surveillance project. J Clin Psychiat. 2000; 61:569-74. (IF 4.454)
  175. Zill P, Bürger K, Behrens S, Hampel H, Padberg F, Boetsch T, Möller HJ, Ackenheil M, Bondy B. Polymorphisms in the a-2 macroglobulin gene in psychogeriatric patients. Neurosci Lett. 2000; 17:69-72. (IF 2.091)
  176. Zill P, Padberg F, de Jonge S, Hampel H, Bürger K, Stübner S, Möller HJ, Ackenheil M, Bondy B. Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. Neurosci Lett. 2000; 284(1-2):113-5. (IF 2.091)
  177. Padberg F, Zwanzger P, Thoma H, Kathmann N, Haag C, Greenberg BD, Hampel H, Möller HJ. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: Comparison of fast, slow and sham rTMS. Psychiat Res. 1999; 88:163-71. (IF 1.551)
  178. Mentis MJ, Alexander GE, Grady CL, Horwitz B, Krasuski J, Pietrini P, Strassburger T, Hampel H, Schapiro MB, Rapoport SI. Frequency variation of a pattern-flash visual stimulus during PET differentially activates brain from striate through frontal cortex. Neuroimage. 1997; 5:116-28. (IF 8.930)
  179. Frenzel KH, Müller N, Heidmann D, Hampel H, Kretzschmar HA, Penning R, Ackenheil M. Expression of T cell teceptor g/d antigens in human brain tissue. Neuroimmunomodulat. 1995; 2:115-20. (IF 1.609)
  180. Müller N, Frenzel KH, Schwarz M, Würl D, Hampel H, Penning R, Ackenheil M. Expression of human heat-shock protein 70 antigens and g/d T-cell receptor antigens in human central nervous tissue. Ann NY Acad Sci. 1994; 741(25):305-15. (IF 0.964).

Review Articles:

  1. Lista S, Dubois B, Hampel H. Paths to Alzheimer’s disease prevention: from modifiable risk factors to biomarker enrichment strategies. J Nutr Health Aging. 2014. Accepted. (IF 2.659 ).
  2. Cavedo E, Lista S, Khachaturian ZS, Aisen PS, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow B, O’Bryant SE, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, Thiebaut de Schotten M, Mangin JF, Lammertsma A, Johnson K, Teipel SJ, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H. The road ahead to cure Alzheimer's Disease: Development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J Prev Alz Dis. IF= -
  3. Lista S, Khachaturian ZS, Rujescu D, Garaci F, Dubois B, Hampel H. Application of systems theory in longitudinal studies on the origin and progression of Alzheimer’s disease. Methods Mol Biol. 2014. Accepted. (IF 1.29).
  4. Lista S, Zetterberg H, Dubois B, Blennow K, Hampel H. Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments. J Neurol. 2014 Jun;261(6):1234-1243. (IF 3.841).
  5. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2014 May 2. doi: 10.1016/j.jalz.2014.02.004. (IF 17.472).
  6. Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15;88(4):426-449. (IF 4.576).
  7. Dubois B, Epelbaum S, Santos A, Di Stefano F, Julian A, Michon A, Sarazin M, Hampel H. Alzheimer disease: from biomarkers to diagnosis. Rev Neurol (Paris). 2013 Oct;169(10):744-51. doi: 10.1016/j.neurol.2013.07.016. (IF 0.510).
  8. Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer's disease. Med Clin North Am. 2013 May;97(3):399-424. (IF 2.467).
  9. Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H. CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement.2014 May;10(3):381-392. (IF 17.472).
  10. Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology. 2014 Jan;39(1):189-201. (IF 7.991).
  11. Aisen P, Vellas B, Hampel H. Moving towards early clinical trials for amyloid‐targeted therapy in Alzheimer’s disease. Nat Rev Drug Discov. 2013 Apr;12(4):324. doi: 10.1038/nrd3842-c1. (IF 29.008).
  12. Hampel H, Lista S. Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?  Alzheimers Res Ther. 2013 Mar 18;5(2):11. (IF 4.39).
  13. Hampel H, Lista S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging. 2013;17(1):54-63. (IF 2.686).
  14. Hampel H, Lista S. Alzheimer disease: From inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol. 2012 Nov 5;8(11):598-600. (IF 15.518).
  15. Hampel H, Lista S. Silent Alarm – The Quiet Epidemic of Alzheimer's Disease. Karger Gazette. 2012. S. Karger AG - Medical and Scientific Publishers Basel, Schweiz (IF –).
  16. Lista S, Garaci FG, Toschi N, Hampel H. Imaging epigenetics in Alzheimer’s disease. Curr Pharm Design. 2013;19(36):6393-415 (IF 3.87).
  17. Hampel H. Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. [Presentation at the conference: The Aging Brain Current Concepts, Intervention Strategies and the Role of Ginkgo Biloba Extract Egb 761, Amsterdam 8-9 June 2011.] Int Psychogeriatr. 2012 Aug;24 Suppl 1:S10-7. (IF 2.478).
  18. Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 2012 Jul;8(4):312-336. (IF 14.483).
  19. Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol. 2013 Feb;101-102:1-17 (IF 9.035).
  20. Lista S, Faltraco F, Hampel H. Biological and methodical challenges of proteomic biomarker research in Alzheimer's disease. Prog Neurobiol. 2013 Feb;101-102:18-34 (IF 9.035).
  21. Teipel SJ, Sabri O, Grothe M, Barthel H, Prvulovic D, Buerger K, Bokde AL, Ewers M, Hoffmann W, Hampel H. Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. J Alzheimers Dis. 2013;33 Suppl 1:S329-S347. doi: 10.3233/JAD-2012-129030. (IF 4.261).
  22. Pruvlovic D, Hampel H. Impact of neuroimaging methods for enrichment, stratification and outcome in Alzheimer’s disease clinical trials. Curr Pharm Design. 2012. (accepted) (IF 3.87)
  23. Faltraco F, Lista S, Garaci FG, Hampel H. Epigenetic mechanisms in Alzheimer’s disease: state-of-the-art. European Journal of Neurodegenerative Diseases. 2012. (accepted) (IF -).
  24. Hampel H. Beta amyloid and cognition in aging and Alzheimer’s disease: Molecular and neurophysiological mechanisms. J Alzheimers Dis. (Special Issue: Alzheimer’s Disease: Advances for a New Century). 2012 Apr 18. (IF 4.261).
  25. Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P; Task Force Participants. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging. 2012 Apr;16(4):339-45. (IF 2.484).
  26. Hampel H, Prvulovic D. Are biomarkers harmful to recruitment and retention in Alzheimer:s disease clinical trials? An international perspective. J Nutr Health Aging. 2012 Apr;16(4):346-348. (IF 2.484).
  27. Karakaya T, Fußer F, Prvulovic D, Hampel H. Treatment options for tauopathies. Curr Treat Options Neurol. 2012 Apr;14(2):126-36 (IF 1.810).
  28. Hampel H, Faltraco F. Möglichkeiten der frühdiagnostik und Hoffnung auf neue Medikamente. Der Privatarzt – Medizin & Management. Ausgabe 2, April 2012, 8–9 (IF –).
  29. Fußer F, Karakaya T, Prvulovic D, Hampel H. Improving the accuracy of dementia diagnosis with functional imaging. Dementia Europe 2012, 4:4-6. (IF –).
  30. Hampel H. Biomarker des Morbus Alzheimer: Schon praxisrelevant? Diagnostische Hilfe in schwierigen Fällen. Current congress zum DGN-Kongress 2011. 2011, p. 10. (IF –)
  31. Noelker C, Hampel H, Dodel R. Serum protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. Mol Diagn Ther. 2011; 15(2):83-102. (IF 2.561)
  32. Ewers M, Frisoni GB, Teipel SJ, Grinberg LT, Amaro E Jr, Heinsen H, Thompson PM, Hampel H. Staging Alzheimer’s disease progression with multimodality neuroimaging. Prog Neurobiol. 2011; 95(4):535-46. Epub 2011 Jun 22. (IF 9.966).
  33. Knöchel C, Oertel-Knöchel V, O’Dwyer L, Prvulovic D, Alves G, Kollmann B, Hampel H. Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog Neurobiol. 2012; 96(1):46-68. Epub 2011 Nov 24. (IF 9.966).
  34. Bertram L, Hampel H. The role of genetics for biomarker development in neurodegeneration. Prog Neurobiol. 2011; 95(4):501-4. Epub 2011 Oct 12. (IF 9.966).
  35. Broich K, Weiergräber M, Hampel H. Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements. Prog Neurobiol. 2011; 95(4):498-500. Epub 2011 Sep 16. (IF 9.966).
  36. Karakaya T, Prvulovic D, Fußer F, Hampel H. Biomarker des Morbus Alzheimer: Schon praxisrelevant? Neuro Aktuell. 6, 2012. (accepted) (IF –).
  37. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends Neurosci. 2011; 34(8):430-42. Epub 2011 Jun 20. (IF 13.320).
  38. Frisoni GB, Hampel H, O’Brien JT, Ritchie K, Winblad B. Revised criteria for Alzheimer’s disease: what are the lessons for clinicians? Lancet Neurol. 2011; 10(7):598-601. (IF 21.659).
  39. Geser F, Prvulovic D, O’Dwyer L, Hardiman O, Bede P, Bokde ALW, Trojanowski JQ, Hampel H. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol. 2011; 95(4):649-62. Epub 2011 Sep 3. (IF 9.966).
  40. Hampel H, Prvulovic D, Teipel SJ, Bokde AL. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer’s disease. Prog Neurobiol. 2011; 95(4):570-8. Epub 2011 Jul 13. (IF 9.966).
  41. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F. The future of Alzheimer’s disease: The next 10 years. Prog Neurobiol. 2011; 95(4):718-28. Epub 2011 Nov 22. (IF 9.966).
  42. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol. 2011; 95(4):579-93. Epub 2010 Dec 2. (IF 9.140).
  43. Nicotera P, Hampel H. Perspectives of worldwide translational biomarker research in neurodegenerative diseases. Prog Neurobiol. 2011; 95(4):496-7. Epub 2011 Jul 23. (IF 9.966).
  44. Oertel-Knöchel V, Bittner RA, Knöchel C, Prvulovic D, Hampel H. Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol. 2011; 95(4):686-702. Epub 2011 Jun 6. (IF 9.966).
  45. Prvulovic D, Bokde AL, Faltraco F, Hampel H. Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. Prog Neurobiol. 2011; 95(4):557-69. Epub 2011 Jun 22. (IF 9.966).
  46. Prvulovic D, Hampel H. Ethical considerations of biomarker use in neurodegenerative diseases – A case study of Alzheimer’s disease. Prog Neurobiol. 2011; 95(4):517-9. (IF 9.966).
  47. Schneider B, Prvulovic D, Oertel-Knöchel V, Knöchel C, Reinke B, Grexa M, Weber B, Hampel H. Biomarkers for major depression and its delineation from neurodegenerative disorders. Prog Neurobiol. 2011; 95(4):703-17. Epub 2011 Aug 12. (IF 9.966).
  48. Trojanowski JQ, Hampel H. Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol. 2011; 95(4):491-5. Epub 2011 Jul 23. (IF 9.966)
  49. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: an EU-US task force report. Prog Neurobiol. 2011; 95(4):594-600. Epub 2011 Sep 10. (IF 9.966)
  50. Hampel H, Ewers M. Comment on “Ergebnisse der PDT-301-Verlaufsstudie und deren Auswirkungen auf die klinische Praxis”. Demenz Forum. 2009; 6:20. (IF -)
  51. Prvulovic D, Hampel H. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med. 2011. 49(3):364-77. (IF 2.029)
  52. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. (IF 6.511)
  53. Buschert V, Bokde ALW, Hampel H. Cognitive Intervention in Alzheimer’s Disease. Nat Rev Neurol. 2010; 6(9):508-17. (IF 6.511)
  54. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol. 2010; 45(1):75-9. (IF 3.342)
  55. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol. 2010; 45(1), 30-40. (IF 3.342)
  56. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010; 9(7):560-74. (IF 29.059)
  57. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer’s disease. Exp Neurol. 2010; 223(2):334-46. (IF 3.914)
  58. Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer’s disease. Expert Opin Drug Met. 2010; 6(3):345-54. (IF 3.076)
  59. Zetzsche T, Rujescu D, Hardy J, Hampel H. Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease. Expert Rev Mol Diagn. 2010; 10(5):667-90. (IF 3.693)
  60. Bokde ALW, Ewers M, Hampel H. Assessing neuronal networks: understanding Alzheimer’s disease. Prog Neurobiol. 2009; 89(2):125-33. (IF 9.130)
  61. Hampel H, Broich K, Hoessler YC, Pantel J. Biological Markers for early detection and pharmacological treatment of Alzheimer’s disease. Dialogues in Clin Neurosci. 2009; 11(2):141-57. (IF -)
  62. Hampel H, Shen Y. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer’s disease. Scand J Clin Lab Inv. 2009; 69(1):8-12. (IF 1.363)
  63. Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer’s disease in blood, plasma, and serum. CNS Neurosci Ther. 2009; 15(4):358-74. (IF 4.432)
  64. Zetzsche T, Omerovic M, Graz C, Hampel H. Pharmakotherapie der Demenz vom Alzheimer-Typ und ihrer zusätzlichen psychopathologischen Begleitsymptome. Facharzt Neurologie/Psychiatrie. 2009; 1/2009:10-6. (IF -)
  65. Hampel H, Buerger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement. 2008; 4(1):38-48. (IF -)
  66. Hampel H, Pantel J. Aktuelle Frühdiagnostik der Alzheimer-Demenz. NeuroTransmitter. 2008; 19(9):26-32. (IF -)
  67. Omerovic M, Hampel H, Teipel SJ, Buerger K. Pharmacological treatment of Alzheimer’s dementia: state of the art and current dilemmas. World J Biol Psychia. 2008; 9(1):69-75. (IF 3.582)
  68. Teipel SJ, Meindl T, Grinberg L, Heinsen H, Hampel H. Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol I. 2008; 35(Suppl 1):S58-69. (IF 4.532)
  69. Hampel H, Bürger K. Neurobiologische Diagnostik der Alzheimer-Demenz. Die Psychiatrie. 2007; 4:12-9. (IF -)
  70. Hampel H, Teipel J, Buerger K. Neurobiologische Frühdiagnostik der Alzheimer-Krankheit. MedReport. 2007; 31:17. (IF -)
  71. Hampel H, Teipel SJ, Bürger K. Neurobiologische Frühdiagnostik der Alzheimer-Krankheit. [Neurobiological early diagnosis of Alzheimer’s disease]. Nervenarzt. 2007; 78(11):1310-8. (IF 0.601)
  72. Omerovic M, Teipel SJ, Hampel H. Demenz mit Lewy-Körperchen – Besserung unter Therapie mit einem Acetylcholinesteraseinhibitor. [Dementia with Lewy bodies – clinical improvement under treatment with an acetylcholinesterase inhibitor]. Nervenarzt. 2007; 78(9):1052-7. (IF 0.601)
  73. Padberg F, Hampel H. Donepezil zur Therapie von Patienten mit kognitiven Veränderungen bzw. Alzheimer-Demenz. Internist (Berl.). 2006; 47:861-3. (IF 0.277)
  74. Sunderland T, Hampel H, Takeda M, Putnam KT, Cohen RM. Biomarkers in the diagnosis of Alzheimer’s disease: are we ready? J Geriatr Psych Neur. 2006; 19(3):172-9. (IF 1.970)
  75. Teipel SJ, Hampel H. Combined evaluation of CSF tau proteins and MRI volumetry in Alzheimer’s disease. Research and Practice in Alzheimer's Disease. 2006; 11:270-5. (IF -)
  76. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer’s disease.Behav Genet. 2006; 36(3):405-15. (IF 2.634)
  77. Bottlender R, Hampel H, Sievers M, Möller HJ. Bei Schizophreniepatienten immer abklären: Steckt hinter den Negativsymptomen eine Depression? Diagnostik und Therapie depressiver Syndrome bei schizophrenen Patienten. MMW – Fortschritte der Medizin. 2005; 147(Spec No 2):59-62. (IF -)
  78. Ewers M, Teipel SJ, Hampel H. Aktuelle Entwicklungen der strukturellen MRT zur Frühdiagnostik der Alzheimer-Demenz. Nervenheilkunde, 2005, 24:113-9. (IF 0.390)
  79. Frölich L, Schmitt B, Calabrese P, Diener H, Förstl H, Gertz H, Ihl R, Rieke J, Riepe M, Supprian T, Hallauer J, Hampel H. Zur Entwicklung von Leitlinien für die Pharmakotherapie bei Alzheimer Krankheit. Arzneimitteltherapie. 2005; 23:181-90. (IF -)
  80. Graz C, Teipel SJ, Hampel H. Morbus Alzheimer: Pharmakotherapie der Erkrankung und ihrer zusätzlichen psychopathologischen Begleitsymptome. Facharzt Neurologie / Psychiatrie. 2005; 1:26-32. (IF -)
  81. Jessen F, Ewers M, Träber F, Teipel SJ, Gür O, Block W, Hampel H. Früh- und Differentialdiagnose von Demenzen – MR-Volumetrie und Protonen-MR-Spektroskopie (Early and differential diagnosis of dementia – MR-volumetry and proton MR-spectroscopy). Nervenheilkunde. 2005; 6:463-9. (IF 0.390)
  82. Padberg R, Möller HJ, Bottlender R, Hampel H. Alltagskompetenzen erhalten, Wohlbefinden steigern. Das sind die Ziele einer modernen antidementiven Therapie. (Modern therapy for dementia). MMW – Fortschritte der Medizin, 2005, 147(2):71-4, 76-7. (IF -)
  83. Teipel SJ, Hampel H. Alzheimer-Krankheit. Aktuelle Perspektiven der Diagnostik und Therapie. Bayerisches Ärzteblatt. 2005; 9:552-6. (IF -)
  84. Teipel SJ, Hampel H. Atrophie von Hippocampus und Amygdala: Indikator eines erhöhten Demenzrisikos? InFo Neurologie und Psychiatrie. 2005; 8:22. (IF -)
  85. Ewers M, SJ Teipel, Graz Ch, Möller HJ, Hampel H. Früherkennung von Demenzen: Radiologische Diagnostik auf dem Vormarsch. Der Neurologe und Psychiater (DNP). 2004; 5:48-54.(IF -)
  86. Frölich L, Fox J, Padberg F, Maurer K, Möller HJ, Hampel H. Targets of antidementive therapy: drugs with a specific pharmacological mechanism of action. Curr Pharm Design. 2004; 10(3):223-9. (IF 5.385)
  87. Hampel H, Blennow K. CSF tau and ß-amyloid as biomarkers for mild cognitive impairment (MCI). Dialogues in Clinical Neuroscience. 2004; 6:379-90. (IF -)
  88. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Möller HJ. Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm. 2004; 111(3):247-72. (IF 2.628)
  89. Hampel H, Teipel SJ. Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal Dementia. Dement Geriatr Cogn. 2004; 17:350-4. (IF 2.493)
  90. Hampel H. Alzheimer Demenz (AD): Neue Wege in der Frühdiagnostik und in der Therapie. Gyne, Zeitschrift für den Frauenarzt. 2004; 25:1-3.(IF -)
  91. Hampel H. Alzheimer-Demenz. Deutsche Apotheker Zeitung (DAZ). 2004; 144(14):52-4.(IF -)
  92. Hampel H. Demenz: Aktueller Stand und neue Wege in Frühdiagnostik und Therapie. Neuro-Psychiatrische Nachrichten, 2004, 3:10.(IF -)
  93. Teipel SJ, Möller HJ, Hampel H. Atypische Neuroleptika: Einsatz bei Demenzkranken? MMW – Fortschritte der Medizin. 2004; 146(42):25.(IF -)
  94. Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer’s disease.Lancet Neurol. 2003; 2(10):605-13. (IF 3.070)
  95. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer’s disease. Lancet Neurol. 2003; 2:215-20. (IF 3.070)
  96. Faltraco F, Teipel SJ, Möller HJ, Hampel H. Aktuelle Therapiemöglichkeiten der Alzheimer Demenz. Neurologie und Rehabilitation. 2003; 9(1):15-22.(IF -)
  97. Faltraco F, Teipel SJ, Möller HJ, Hampel H. Leichte kognitive Störung oder Alzheimer – So wirken Antidementiva. Ärztliche Praxis Neurologie Psychiatrie. 2003; 5:40-4.(IF -)
  98. Fuchsberger T, Möller HJ, Hampel H. Aktuelle Antidementiva – Demenzkranken steht eine moderne Therapie zu. MMW – Fortschritte der Medizin. 2003; 145(2):49-52,54.(IF -)
  99. Fuchsberger T, Möller HJ, Hampel H. Behandlung der Alzheimererkrankung. Aktueller Stand der Pharmakotherapie. Der niedergelassene Arzt. 2003;9:32-4.(IF -)
  100. Fuchsberger T, Möller HJ, Hampel, H. Demenzpatienten: Was spricht für neue, was für alte Antiagitativa? Geriatrie Journal. 2003; 9:12-7.(IF -)
  101. Hampel H, Fuchsberger T, Möller HJ. Alzheimer: Aktueller Stand der Pharmakotherapie. Wirtschaftsmagazin für den Nervenarzt. 2003; 12:19-21.(IF -)
  102. Hampel H, Görnitz A, Bürger K. Advances in the development of biomarkers for Alzheimer’s disease. From CSF total tau and Aß1-42 proteins to phosphorylated tau protein. Brain Res Bull. 2003; 61(3):243-53. (IF 2.609)
  103. Hampel H, KamHead M, Möller HJ. Zukunftsstrategien in der Pharmakotherapie der Alzheimerdemenz. Medical Journal. 2003; 3:1-2.(IF -)
  104. Hampel H, Möller HJ. Neue Wege der Frühdiagnostik und Therapie der Alzheimer Demenz. MedReport. 2003; 10:1-4.(IF -)
  105. Faltraco F, Fuchsberger T, Padberg F, Bürger K, Möller HJ, Hampel H. Behandlung von psychischen Störungen und Komorbidität. Hausarzt Kolleg – Neurologie & Psychiatrie. 2002; 1(2):32-4. (IF -)
  106. Fuchsberger T, Faltraco F, Möller HJ, Hampel H. Differenzialdiagnose der beginnenden Demenz und Depression. Wo therapeutisch ansetzen? InFo Neurologie und Psychiatrie. 2002; 4(6):446-9.(IF -)
  107. Fuchsberger T, Faltraco F, Möller HJ, Hampel H. Kognitive Beeinträchtigung bei depressiver Episode – Kasuistik und CME Fragen. InFo Neurologie und Psychiatrie. 2002; 4(6):449-51.(IF -)
  108. Fuchsberger T, Padberg F, Bürger K, Hampel H. Antidementive Therapie der Alzheimer-Demenz – Current Therapeutical Strategies in Alzheimer’s Dementia. Psycho. 2002; 28(1):32-8. (IF -)
  109. Fuchsberger T, Padberg F, Bürger K, Möller HJ, Faltraco F, Hampel H. Antidementive Therapie der Alzheimer Demenz. Hausarzt Kolleg – Neurologie & Psychiatrie. 2002; 1(2):25-31. (IF -)
  110. Fuchsberger T, Padberg F, Faltraco F Möller HJ, Hampel H. Alzheimer Therapie möglichst im Frühstadium beginnen. MMW – Fortschritte der Medizin. 2002; 144(20):36-9.(IF -)
  111. Hampel H, Bürger K, Zinkowski R, Teipel SJ, Kohnken R, Kerkman D, DeBernardis J, Kahle P, Rapoport SI, Sunderland T, Arai H, Tapiola T, Hofmann-Kiefer K, Andreasen N, Blennow K, Moller HJ, Davies P. CSF tau phosphorylated at threonine 231, total tau and neuronal thread protein in the diagnosis of Alzheimer's disease. Eur Psychiat. 2002; 17 Suppl 1:77. (IF 1.327)
  112. Hampel H, Möller HJ. Alzheimer Patienten in jedem Fall behandeln: Es “dämmert” am Therapiehorizont” (Editorial). MMW – Fortschritte der Medizin. 2002; 144(20):29. (IF -)
  113. Huell M, Hampel H. Neuroinflammation in Alzheimer's disease: potential targets for disease-modifying drugs.Ernst Schering Research Foundation Workshop. 2002; 39:159-78.(IF -)
  114. Hüll M, Hampel H. Neue Ansätze in der Therapie der Demenz. MMW – Fortschritte der Medizin. 2002; 144(20):40-1. (IF -)
  115. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol. 2001; 24(1-3):87-97. (IF 2.095)
  116. Padberg F, Hampel H, Möller HJ. Alzheimer Patienten mit Antidementiva behandeln. MMW – Fortschritte der Medizin. 2001; 143(51-52):43-5. (IF -)
  117. Padberg F, Hampel H, Möller HJ. Alzheimer-Patienten mit Antidementiva behandeln trotz unbeantworteter Fragen (Editorial). MMW – Fortschritte der Medizin Orig, 2001, 119(3-4):141-3. (IF -)
  118. Auer S, Hampel H, Möller HJ, Reisberg B. Translations of measurements and scales: opportunities and diversities. Int Psychogeriatr. 2000; 12(1):391-4. (IF -)
  119. Bürger K, Hampel H, Neumann M, Möller HJ, Kretzschmar H. Autopsie bringt neue Erkenntnisse über die Alzheimer-Demenz. MMW – Fortschritte der Medizin. 2000; 142(39):40-1.(IF -)
  120. Bürger K, Teipel SJ, Hampel H. Alzheimer – schon Jahre vor den ersten Symptomen erkennbar? MMW – Fortschritte der Medizin. 2000; 142(16):26-30. (IF -)
  121. Frölich L, Padberg F, Kratzsch T, Maurer K, Möller HJ, Hampel H. Therapie der Alzheimer-Demenz – Aktueller Stand und Perspektiven. MMW – Fortschritte der Medizin. 2000; 142(25):30-4.(IF -)
  122. Hampel H, Möller HJ. Alzheimer Demenz – Schenken Sie Ihrem Patienten noch ein wenig Lebensqualität! (Editorial). MMW – Fortschritte der Medizin. 2000; 142(25):9. (IF -)
  123. Hampel H, Möller HJ. Hoffnung für Demenzkranke – Neue Methoden zur Frühdiagnose. (Editorial). MMW – Fortschritte der Medizin. 2000; 142(16):25. (IF -)
  124. Kötter HU, Hampel H. Alte Mythen verhindern die Therapie – Gedächtnisstörungen sind nicht Ausdruck “normaler” Senilität. MMW – Fortschritte der Medizin. 2000; 142(25):35-6. (IF -)
  125. Möller HJ, Padberg F, Hampel H. Aktueller Stand der Therapie mit Nootropika / Antidementiva. Med-Report. 2000; 25(24):6. (IF -)
  126. Wagner J, Bürger K, Möller HJ, Hampel H. Kommentar: Wirksamkeit und Unbedenklichkeit von Rivastigmin bei Patienten mit Morbus Alzheimer: eine internationale, randomisierte Prüfung. InFo Neurologie & Psychiatrie. 2000; 2:19. (IF -)
  127. Zoghlache MD, Bürger K, Schück S, Möller HJ, Rapoport SI, Allain H, Hampel H. Thérapie multiconceptuelle dans la maladie d’Alzheimer. Presse Médicale. 2000; 29(21):1197-201. (IF 0.441)
  128. Bürger K, Hampel H, Möller HJ. Kommentar: Die Wirksamkeit von Ginkgo biloba auf die kognitive Funktion bei der Alzheimer Demenz. InFo Neurologie & Psychiatrie. 1999; 1(4):230-1. (IF -)
  129. Hampel H, Padberg F, Buch K, Unger J, Stübner S, Möller HJ. Diagnose und Therapie der Alzheimer Demenz. Deut Med Wochenschr. 1999; 5:124-9. (IF 0.684)
  130. Kötter HU, Möller HJ, Hampel H. Sertralin – Ein moderner selektiver Serotonin-Wiederaufnahme-hemmer in der antidepressiven Therapie multimorbider Patienten. Arzneimitteltherapie. 1999; 17(12):395-402. (IF -)
  131. Padberg F, Stübner S, Buch K, Boetsch T, Ehrhardt T, Möller HJ, Hampel H. Aktuelle Therapiemöglichkeiten der Alzheimer-Demenz. Medizinische Welt. 1999; 50:105-13. (IF 0.059)
  132. Retz W, Rösler M, Möller HJ, Hampel H. Rivastigmin. Ein Acetylcholinesterasehemmer der zweiten Generation zur Behandlung der Alzheimer Demenz. Arzneimitteltherapie. 1999; 17(7):213-8. (IF -)
  133. Teipel SJ, Bartenstein P, Alexander GE, Möller HJ, Rapoport SI, Hampel H. In vivo neuroreceptor imaging and applications for Alzheimer’s disease. Drug News Perspect. 1999; 12(6):341-50. (IF 0.462)
  134. Teipel SJ, Hampel H, Pietrini P, Möller HJ, Rapoport SI. PET in Alzheimer’s disease – from resting-state to activation studies. Drug News Perspect. 1999; 12(2):83-90. (IF 0.462)
  135. Wagner J, Bürger K, Möller HJ, Hampel H. Kommentar: Die Beeinträchtigung der kognitiven Leistungsfähigkeit bei geriatrischen, chronisch hospitalisierten Schizophreniepatienten. InFo Neurologie & Psychiatrie. 1999; 1(6):424-5. (IF -)
  136. Ehrhardt T, Hampel H, Hegerl U, Möller HJ. Das Verhaltenstherapeutische Kompetenztraining VKT – Eine spezifische Intervention für Patienten mit einer beginnenden Alzheimer-Demenz. Z Gerontol Geriatr. 1998; 31:112-9. (IF -)
  137. Hampel H, Berger C, Buch K, Möller HJ. Treatment of elderly psychiatric patients with the reversible MAO-A inhibitor moclobemide. Human Psychopharmacology. 1998; 13:43-51. (IF 0.609)
  138. Hampel H, Berger C, Padberg F, Haslinger A, Haberl A, Hock C, Hofmann M, Stübner S, Buch K, Boetsch T, Ehrhardt T, Möller HJ, Ackenheil M, Müller-Spahn F. Demenz vom Alzheimer Typ: Liquor Immunglobuline und Blut-Hirn-Schranke. Geriatrie Forschung. 1998; 8(2):93-102. (IF -)
  139. Hampel H, Möller HJ. Donepezil-Pharmakotherapie der Alzheimer Demenz mit einem Acetylcholinesterase Hemmer der zweiten Generation. Arzneimitteltherapie. 1998; 4:102-6. (IF -)
  140. Hampel H, Padberg F, Gorriz C, Frölich L, Kötter HU, Buch K, Pfluger Th, Dick S, Hegerl U, Möller HJ, Müller-Spahn F. Hilfreiche Strategien für die Differentialdiagnostik kognitiver Störungen. Geriatrie Praxis. 1998; 12:16-22. (IF -)
  141. Hampel H, Padberg F, Möller HJ. Pharmakotherapie der Alzheimer Demenz durch Acetylcholinesterase-Hemmer der zweiten Generation: Donepezil. Psychopharmakotherap. 1998; 2:54-61. (IF 0.197)
  142. Hampel H. Möglichkeiten der Therapie mit Acetylcholinesterase-Hemmern. Geriatrie Praxis. 1998; 9:12. (IF -)
  143. Kötter HU, Hampel H. Komorbidität dementieller Erkrankungen – sind Alzheimer-Patienten körperlich gesünder? Fortschritte der Medizin. 1998; 9:44-6. (IF -)
  144. Pietrini P, Bartenstein P, Teipel SJ, Hampel H. Positron Emission Tomography and the effect of aging and neurodegeneration on brain function. Part I: Basic principles of PET technology. Drug News Perspect. 1998; 11(3):161-5. (IF -)
  145. Berger C, Müller-Spahn F, Kuss HJ, Möller HJ, Hampel H. Trizyklische Antidepressiva als mögliche Ursache erschwerter oraler Antikoagulation. Psychopharmakotherap. 1997; 4(1):23-8. (IF 0.197)
  146. Hampel H, Padberg F, Kötter HU, Teipel SJ, Ehrhardt T, Hegerl U, Stübner S, Möller HJ. Diagnose und Therapie der Demenz vom Alzheimer Typ. MMW – Münchener Medizinische Wochenschrift. 1997; 139(36):506-11. (IF -)
  147. Hampel H, Padberg F, Möller HJ, Berger C. Pharmakotherapie älterer Patienten mit dem selektiven MAO-A-Inhibitor Moclobemid. Psychopharmakotherap. 1997; 4:59-65. (IF 0.197)
  148. Hampel H, Padberg F, Unger J, Kötter HU, Möller HJ. Die Suche nach den Ursachen der Alzheimer Demenz. MMW – Münchener Medizinische Wochenschrift. 1997; 139(36):506-10. (IF -)
  149. Hampel H, Teipel SJ, Kötter HU, Horwitz B, Pfluger T, Mager T, Möller HJ, Müller-Spahn F. Strukturelle Magnet Resonanz Tomographie in der Diagnose und Erforschung der Alzheimerschen Erkrankung. Nervenarzt. 1997; 68:365-78. (IF 0.684)
  150. Kötter HU, Stübner S, Möller HJ, Hampel H. Die Bedeutung der Komorbidität bei der Demenz vom Alzheimer Typ. MMW – Münchener Medizinische Wochenschrift. 1997; 139(36):518-20. (IF -)
  151. Padberg F, Hampel H. Value of early detection of cognitive decline. Preventing Cognitive and Neurosensory Decline. 1997; 27:2-4. (IF -)
  152. Hampel H, Berger C, Möller HJ, Müller-Spahn F. Oral anticoagulation under the influence of reversible and irreversible MAO inhibitors. Human Psychopharmacology. 1996; 11:69-71. (IF 0.609)
  153. Hampel H, Berger C, Müller-Spahn F. Psychodrug-induced and EDTA-associated thrombocytopenia: important factors in the differential diagnosis of low platelet counts. Eur Psychiat. 1996; 11:416-8. (IF 0.591)
  154. Hampel H, Müller-Spahn F, Panradl U, Berger C. Niedrige Plättchenzahlen in Klinik und Praxis. MMW – Münchener Medizinische Wochenschrift. 1996; 138(15):268-71. (IF -)
  155. Hampel H, Schneider C, Schwarz HJ, Kötter HU, Müller N, Ackenheil M. Cell Adhesion Molecules in the CNS: Perspectives for psychiatric and neurological disorders. Drug News Perspect. 1996; 9(2):69-81. (IF 0.462)
  156. Kötter HU, Hampel H, Möller HJ. Dementia or Depression: Differential diagnosis when symptoms overlap. Alzheimer Insights. 1996; 2(1):5-9. (IF -)
  157. Hampel H, Müller N. Inflammatory and Immunological Mechanisms in Alzheimer’s disease. Drug News Perspect. 1995; 8(10):599-608. (IF 0.462)

Co-Author (27) (134,750):

  1. O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman RA, Fagan AM, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R, for the STAR-B and BBBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement. Accepted. IF=17.472
  2. Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci. 2014 Aug 26. DOI 10.1007/s00406-014-0521-9. (IF 3.355).
  3. Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci. 2014 Aug 14. doi: 10.1007/s00406-014-0520-x. (IF 3.355).
  4. B. Vellas, C. Sampaio, R. Bateman, A. Boxer, M.C. Carrillo, J. Cummings, B. Dubois, H. Hampel, R. Katz, Z. Khachaturian, S. Gauthier, K. Johnson, J. Karlawish, M. Mintun, R. Petersen, M. Rafii, P. Robert, L. Schneider, E. Siemers, R.Sperling, P. Tariot, J. Touchon, M. Weiner, S. AndrieuP. Aisen and Task Force Members*. E.U./U.S. CTAD task force on Alzheimer’s trial populations. The Journal of Prevention of Alzheimer’s Disease – JPAD. 2014;1(1)(IF - )
  5. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-629. (IF 21.823 ).
  6. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW; Blood-Based Biomarker Interest Group. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2014 Jan;10(1):115-31. doi: 10.1016/j.jalz.2013.01.013. (IF 17.472).
  7. Kilimann I, Likitjaroen Y, Hampel H, Teipel S. Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's disease. Curr Pharm Des. 2013;19(36):6416-6425. (IF 4.774).
  8. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian ZS, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P, and the EU/US/CTAD Task Force Members. Designing Drug Trials for Alzheimer’s Disease : What we have learned from  the release of the Phase III antibody trials: A Report from the E.U./U.S./C.T.A.D Task Force. Alzheimer’s & Dementia 2013;9:438–444 (IF 17.472).
  9. Khachaturian Z, Lane R, Berman R, Cedarbaum JM, Hampel H , Khachaturian A. Are disease modifying treatments still a reasonable goal? J Nutr Health Aging. 2013. (accepted). (IF 2.686)
  10. Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stoeffler A, Streffer J, Berg D. Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics. J Neural Transm. 2012; 119(1):39-52. Epub 2011 Jul 14. (IF 2.597)
  11. Buschert VC, Teipel SJ, Hampel H, Bürger K. Kognitionsbezogene Interventionen bei Alzheimer-Krankheit. [Current status of cognition-based interventions in Alzheimer’s disease]. Nervenarzt. 2009; 80(3):273-87. (IF 0.838)
  12. Carrillo MC, Blackwell A, Hampel H, Lindborg J, Sperling R, Schenk D, Sevigny JJ, Ferris S, Bennett DA, Craft S, Hsu T, Klunk W. Early risk assessment for Alzheimer’s disease. Alzheimers Dement. 2009; 5(2):182-96. (IF -)
  13. Moeller T, Born C, Reiser MF, Möller HJ, Hampel H, Teipel SJ. Alzheimer-Krankheit und vaskuläre Demenz – Bestimmung der Atrophie des Corpus callosum und des zerebralen Kortex. [Alzheimer’s disease and vascular dementia – determination of atrophy of the corpus callosum and cerebral cortex]. Nervenarzt. 2009; 80(1):54-61. (IF 0.838)
  14. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. (IF 25.800)
  15. Diehl J, Monsch AU, Marksteiner J, Romero B, Wolter D, Calabrese P, Mauerer C, Hampel H, Staehelin HB, Kurz A. Diagnostik und Therapie dementieller Erkrankungen – Erfahrungen aus deutschsprachigen Memory-Kliniken. Neurogeriatrie. 2005; 1:1-11. (IF -)
  16. Frölich L, Schmitt B, Calabrese P, Diener H, Förstl H, Gertz HJ, Hallauer JF, Hampel H, Ihl R, Rieke K, Riepe M, Supprian T. Neue Optionen in der Pharmakotherapie der Alzheimer-Krankheit nach der Zulassung von Memantine? [Pharmacotherapy of Alzheimer's disease: New options after the registration of memantine?]. Deut Med Wochenschr. 2005; 130(8):408-12. (IF 0.653)
  17. Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychia. 2005; 6(2):69-84. (IF 2.800)
  18. Diehl J,  Staehelin H, Wiltfang J, Hampel H, Calabrese P, Monsch A, Schmid R, Romero B, Schunk M, Kuhlmann HP, Wolter-Henseler DK, Mauerer C, Stoppe G, Kurz A für die deutschsprachigen Memory-Kliniken. Erkennung und Behandlung der Demenz in den deutschsprachigen Memory-Kliniken: Empfehlungen für die Praxis. Z Gerontol Geriatr. 2003; 36(3):189-96. (IF 0.629)
  19. Frank RA, Galasko D, Hampel H, Hardy J, De Leon M, Mehta DP, Rogers J, Siemers E, Trojanowski QJ. Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease, Neurobiol Aging. 2003; 24(4):521-36. (IF 5.552)
  20. Leinsinger G, Teipel SJ, Wismüller A, Born C, Meindl T, Flatz W, Schoenberg SO, Pruessner J, Hampel H, Reiser M. MR-Volumetrie zur Darstellung von Verteilung und zeitlicher Abfolge neokortikaler Degeneration bei Morbus Alzheimer. Radiologe. 2003; 43(7):537-42. (IF 0.626)
  21. Kohler J, Riepe MW, Jendroska K, Pilartz H, Adler G, Berger FM, Calabrese P, Frölich L, Gertz HJ, Hampel H, Haupt M, Mielke R, Paulus HJ, Zedlick D. Frühdiagnostik und Therapie der Alzheimer Demenz – Sorgfältige Dokumentation schützt vor Regress. MMW – Fortschritte der Medizin. 2002; 144(47):53-4. (IF 0.180)
  22. Kohler J, Riepe MW, Jendroska K, Pilartz H, Adler G, Berger FM, Calabrese P, Frölich L, Gertz HJ, Hampel H, Haupt M, Mielke R, Paulus HJ, Zedlick D. Frühdiagnostik und Therapie der Alzheimer-Krankheit. Zum Vorgehen in der Praxis. MMW – Fortschritte der Medizin. 2002; 144(4):135-41. (IF 0.180)
  23. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M, Landreth G, Lue L-F, Mrak R, Mackenzie IR, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray A. [Proceedings of the Neuroinflammation Working Group]. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000; 21(3):383-421. (IF 4.159)
  24. Pietrini P, Alexander GE, Furey ML, Hampel H, Guazzelli M. The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. Int J Psychophysiol. 2000; 37(1):87-98. (IF 1.489)
  25. Wahlund L-O, Erkinjuntti T, Doraiswamy PM, Hampel H, Waldemar G. Section IV: New techniques and approaches. Proceedings of the 1998 workshop on neuroimaging research in Alzheimer’s disease (Organizers: De Leon MJ, Scheltens P, Section chairs: Jagust W, Small G, DeCarli C, Wahlund L-O). Neuroscience News. 2000; 3:37-45.(IF -)
  26. Adler G, Frölich L, Gertz HJ, Hampel H, Haupt M, Jendroska K, Kurz A, Mielke R, Müller-Thomsen T, Zedlick D. Diagnostik und Therapie der Demenz in der Primärversorgung. ZFA Zeitschrift für Allgemeinmedizin. 1999; 75(21-22):2-6. (IF -)
  27. Ehrhardt T, Kötter HU, Hampel H, Schaub A, Hegerl U, Möller HJ. Psychologische Therapieansätze bei Demenz. Zeitschrift für Gerontopsychologie und -psychiatrie, 1997, 10(2):85-98. (IF -)

Book Chapters (75)

  1. Grothe M, Kurth J, Hampel H, Krause B, Teipel S. Standardization of MRI and amyloid imaging. In: Global Clinical Trials for Alzheimer's Disease: A Manual for Design, Standardization & Implementation. 2013.
  2. Hampel H. Frühdiagnostik. In: Alzheimer – unabwendbares Schicksal? Moderne Wege zu mentaler Gesundheit (Ed. Flöel Agnes). Schattauer GmbH, Stuttgart, Germany, 2013, 27–44.
  3. Frölich L, Hausner L, Hampel H. Diagnostik und Therapie demenzieller Syndrome (ICD 10 F0). In: Therapie psychischer Erkrankungen - State of the Art. Herausgeber: Voderholzer U, Hohagen F. Urban & Fischer Verlag, München, Germany, 2012, 8. Aufl., Kapitel 1, 1-24.
  4. Hampel H, Graz C, Zetzsche T, Rijescu D, Möller HJ. Therapie und Betreuung von Demenzkranken. Pharmakotherapie. In: Demenzen (Eds.: Wallesch CW, Förstl H),  Georg Thieme Verlag KG, Stuttgart, Germany, 2012, 356–370.
  5. Hampel H, Prvulovic D. Leuchtturm-Projekte in der Demenzforschung. In: Personalakquise im Krankenhaus. Ärzte gewinnen, binden, entwickeln (Eds.: Kirchner H, Schroeter M, Flesch M). Springer, Berlin, Heidelberg, 2012, 106-111. 
  6. Broich K, Schlosser G, Weiergräber M, Hampel H. Regulatory requirements on clinical trials in Alzheimer’s disease. In: Alzheimer's Disease – Modernizing Concept, Biological Diagnosis and Therapy (Eds.: Hampel H, Carrillo M). Karger Verlag, Basel, 2012.
  7. Schneider B, Weber B, Hampel H. Depression im Alter. In: Depressive Störungen über die Lebensspanne (Eds.: Freitag CM, Barocka A, Fehr C, Grube M, Hampel H), Kohlhammer, Stuttgart, 2012. (in press)
  8. Teipel S, Sperling R, Skudlarski P, Jack C, Hampel H, Fellgiebel A, Herholz K. MRI and PET based imaging markers for the diagnosis of Alzheimer disease. In: Alzheimer's Disease – Modernizing Concept, Biological Diagnosis and Therapy (Eds.: Hampel H, Carrillo M). Karger Verlag, Basel, 2012.
  9. Zetterberg H, Hampel H, Blennow K. Diagnostic tools: fluid biomarkers for Alzheimer’s disease. In: Alzheimer's Disease – Modernizing Concept, Biological Diagnosis and Therapy (Eds.: Hampel H, Carrillo M). Karger Verlag, Basel, 2012.
  10. Bokde ALW, Karmann, M, Born C, Teipel SJ, Omerovic M, Ewers, M, Frodl T, Meisenzahl E, Reiser M, Möller HJ, Hampel H. Verbal working memory in amnestic mild cognitive impaired subjects: an fMRI study. In: Handbook of Alzheimer’s Disease. ¨¨¨. (accepted)
  11. Hampel H, Prvulovic D. Diagnostik demenzieller Syndrome. In: Therapie psychischer Erkrankungen. State of the Art 2011/2012 (Eds.: Voderholzer U, Hohagen F). 7. Auflage, Urban & Fischer/Elsevier, München, 2011, 2-9.
  12. Frölich L, Hampel H, Hausner L, Prvulovic D, Müller-Spahn F. Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). In: Therapie psychischer Erkrankungen: State of the Art 2011/2012 (Eds.: Voderholzer U, Hohagen F), Urban & Fischer, München, Germany, 2011, 1–18.
  13. Buschert VC, Bokde ALW, Hampel H. Kognitionsbezogene Interventionen bei leichter kognitiver Beeinträchtigung. In: Demenz psychosozial behandeln. Psychosoziale Interventionen bei Demenz in Praxis und Forschung (Eds.: Haberstroh J, Pantel J). AKA Verlag, Heidelberg, 2011, 79-90.
  14. Hampel H, Pantel J. Demenz. In: Psychiatrie, Psychosomatik, Psychotherapie (Eds.: Möller HJ, Laux G, Kapfhammer HP), 4th Edition. Springer Medizin, Berlin, Heidelberg, New York, 2011, Vol. 2, 31-110.
  15. Frölich L, Hampel H, Hausner L, Prvulovic D, Müller-Spahn F. Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0). In: Therapie psychischer Erkrankungen. State of the Art 2010/2011 (Eds.: Voderholzer U, Hohagen F). 6. Auflage, Urban & Fischer/Elsevier, München, 2010, 2-20.
  16. Hampel H, Graz C, Teipel S. Allgemeines zu Demenzen. In: Lehrbuch Neurologie. Ihr roter Faden durchs Studium nach der neuen ÄAppO (Eds.: Dodel R, Klockgether T), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2010, 387-93.
  17. Hampel H, Graz C, Teipel S. Leichte kognitive Störung (LKS). In: Lehrbuch Neurologie. Ihr roter Faden durchs Studium nach der neuen ÄAppO (Eds.: Dodel R, Klockgether T), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2010, 393-96.
  18. Hampel H, Graz C, Teipel SJ. Alzheimer-Demenz. In: Lehrbuch Neurologie. Ihr roter Faden durchs Studium nach der neuen ÄAppO (Eds.: Dodel R, Klockgether T), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2010, 396-413.
  19. Hampel H, Graz C, Teipel S. Frontotemporale Demenzen. In: Lehrbuch Neurologie. Ihr roter Faden durchs Studium nach der neuen ÄAppO (Eds.: Dodel R, Klockgether T), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2010, 413-18.
  20. Pantel J, Hampel H. Blood and cerebrospinal fluid biological markers for Alzheimer’s disease. In: Dementia (Ed.: Ames D, Burns A, O’Brien J), 4th Edition, Hodder Arnold, London, 2010, 459-71.
  21. Jessen F, Hampel H. MRI as a surrogat marker in clinical trials in Alzheimer’s disease. In: Imaging the Aging Brain (Ed.: Jagust W, D’Esposito M), Oxford University Press, USA, 2009, 305-18.
  22. Bürger K, Hampel H. Chapter 23: Biomarkers for the Dementias. In: The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias (Ed.: Weiner MF, Lipton AM), American Psychiatric Publishing, USA, 2009, 407-21.
  23. Hampel H, Bürger K, Hößler Y. Professionelles Projektmanagement – Der Erfolgsfaktor für Lehre und Forschung. In: Professionelles Management im Krankenhaus – Erste Hilfe für leitende Ärztinnen und Ärzte (Ed.: Kirchner H, Kirchner W), Thieme, Stuttgart, 2009, 279-96.
  24. Teipel SJ, Grinberg LT, Hampel H, Heinsen H. Cholinergic system imaging in the healthy aging process and Alzheimer disease. In: Encyclopedia of Neuroscience (Ed.: Squire L, et al.), Elsevier Books, Oxford, UK, 2008, 119-29.
  25. Hampel H. Alzheimer Memorial Centre & Geriatric Psychiatry Research Branch. In: The University Department of Psychiatry in Munich – From Kraepelin and his predecessors to molecular psychiatry (Ed.: Hippius H, Möller HJ, Müller N, Neundörfer-Kohl G), Springer Medizin Verlag, Heidelberg, 2008, 219-21.
  26. Hampel H, Bürger K, Teipel SJ. Kapitel 44: Demenz. In: Psychiatrie und Psychotherapie, 3. Auflage, Band 2 Spezielle Psychiatrie” (Ed.: Möller HJ, Laux G, Kapfhammer HP), Springer Verlag, Berlin, 2008, 13-86.
    • Hampel H, Möller HJ. Ausblick. In: Antidementiva – Physiologie, Pharmakologie und klinische Anwendung (Ed.: Gleiter CH, Volz HP), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2007,182-92.
    • Sunderland T, Hampel H, Takeda M, Putnam KT, Cohen RM. Biomarkers in the Diagnosis of Alzheimer’s Disease: Are We Ready? In: Diagnostic Issues in Dementia: Advancing the Research Agenda for DSM-V (Ed.: Sunderland T, Jeste DV, Baiyewu O, Sirovatka PJ, Regier DA), American Psychiatric Association, Arlington, Virginia, 2007, 99-115.
    • Hampel H, Bürger K. Biomarkers in blood and cerebrospinal fluid. In: The dementias: Early diagnosis and evaluation (Ed.: Perani D, Morris C & Herholz K), Taylor & Francis, 2007, 73-108.
    • Padberg F, Möller HJ, Hampel H. Pharmakotherapie demenzieller Erkrankungen. In: Therapie psychiatrischer Erkrankungen (Ed.: Möller HJ), Thieme, Stuttgart, 2006, 554-77.
    • Rupprecht R, Hampel H. Grundlagen der Psychiatrie und Psychotherapie – Editorial. In: Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO (Ed.: Rupprecht R, Hampel H), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006, 1.
    • Rupprecht R, Hampel H. Editorial der Herausgeber. In: Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO (Ed.: Rupprecht R, Hampel H), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006, V-VI.
    • Hampel H, Teipel SJ. Organische (einschließlich symptomatische) psychische Störungen – Editorial. In: Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO (Ed.: Rupprecht R, Hampel H), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006, 149.
    • Hampel H, Graz C, Teipel SJ. Demenzerkrankungen. In: Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO (Ed.: Rupprecht R, Hampel H), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006, 156-69.
    • Hampel H, Graz C, Teipel SJ. Alzheimer-Krankheit. In: Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO (Ed.: Rupprecht R, Hampel H), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006, 170-87.
    • Hampel H, Graz C, Teipel SJ. Therapie der Demenzerkrankungen. In: Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO (Ed.: Rupprecht R, Hampel H), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006, 217-26.
    • Schoonenboom N, Hampel H, Scheltens P, de Leon M. Cerebrospinal fluid markers for the diagnosis of Alzheimer’s disease. In: Alzheimer’s Disease and Related Disorders Annual 5 (Ed.: Gauthier S, Scheltens P, Cummings JL), 2006 Taylor & Francis, an imprint of the Taylor &Francis Group, 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN, 2006.
    • Teipel SJ, Hampel H. Combined evaluation of CSF tau proteins and MRI volumetry in Alzheimer’s disease. In: Research and Practise in Alzheimer’s disease (Ed.:Vellas B, Winblad B, Grundman M, Fitten LJ, Feldman H, Giacobini E, Kurz A), Serdi Publisher, Paris, 2005, 6 pages.
    • Hampel H. [Diverse Beiträge: Anticholinergika, Cannabinoide, Canabis, Pharmakokinetik, Plasmaspiegel, Restless legs.] In: Therapielexikon Psychiatrie, Psychosomatik & Psychotherapie (Ed.: Zaudig M, Trautmann-Sponsel RD, Joraschky P, Möller HJ, Rupprecht R, Saß H), Springer Verlag, Berlin 2005, 800 pages.
    • Hampel H, Graz C, Möller HJ. Therapie und Betreuung von Demenzkranken – Pharmakotherapie der Demenzen. In: Demenzen (Ed.: Wallesch CW, Förstl H), Thieme, Stuttgart, 2005, 274-87.
    • Hampel H. Neue Wege der Diagnostik und Therapie bei Alzheimer-Demenz, aktueller Stand und Zukunftsperspektiven. In: Gerontopsychiatrie als interdisziplinäre Aufgabe (Ed.: Möller HJ, Hampel H, Hirsch RD, Gutzmann H, Kortus R, Teising), Schriftenreihe der Deutschen Gesellschaft für Gerontopsychiatrie und -psychotherapie, Band 5, Berlin, Bonn, Frankfurt, Saarbrücken, 2004, 223-31.
    • Hampel H, Graz C. Aktuelle Pharmakotherapie der Alzheimer Demenz. In: Anti Aging Medizin (Ed.: Wolf A, Römmler A, Moltz L, Klentze M), Congress Compact Verlag, Berlin, 2004, 18-31.
    • Hampel H, Teipel SJ, Faltraco F, Brettschneider S, Goernitz A, Buerger K, Moeller HJ. Advances in the development of biomarkers for Alzheimer’s disease – From CSF total tau and Ab1-42 proteins to phosphorylated tau and amyloid-b-antibodies. In: Molecular Neurobiology of Alzheimer’s disease and related disorders (Editors: Takeda M, Tanaka T, Cacabelos R), Karger, Basel, 2004, 134-56.
    • Kötter HU, Hampel H. Mythos Alzheimer-Demenz – ein Krankheitsbegriff im Wandel. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 14-27.
    • Bürger K, Wagner J, Wiltfang J, Hampel H. Labortechnische Untersuchungen. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 174-86.
    • Teipel SJ, Hampel H.: Bildgebende Verfahren. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 207-34.
    • Bürger K, Bereznai B, Hampel H. Vaskuläre Demenz. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 270-91.
    • Padberg F, Hampel H. Pharmakotherapie I: Behandlung mit Antidementiva. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 338-76.
    • Padberg F, Karger A, Hampel H, Haupt M. Pharmakotherapie II: Behandlung nicht-kognitiver Symptome. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 377-91.
    • Haupt M, Bürger K, Karger A, Hampel H. Angehörigen- und Sozialbetreuung. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 414-¨.
    • Hampel H, Teipel SJ, Faltraco F, Pruessner JC, Bürger K.: Entwicklung von Positivkriterien zur Diagnose der Alzheimer-Demenz mithilfe bildgebender Verfahren und biologischer Marker – Perspektiven der klinischen Alzheimer-Forschung. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, 426-55.
    • Hampel H, Teipel SJ. Bildgebende Verfahren bei der Frühdiagnose, Verlaufs- und Therapieevalutation. In: Alzheimer-Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien (Ed.: Hampel H, Padberg F, Möller HJ), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2003, ¨.
    • Hampel H, Bürger K, Fuchsberger T. Kapitel 41: Demenzerkrankungen. In: Psychiatrie und Psychotherapie, 2. Auflage (Ed.: Möller HJ, Laux G, Kapfhammer HP), Springer Verlag, Berlin, 2002, 882-940.
    • Hampel H, Scheloske M, Haslinger A. The interleukin-6 receptor complex. In: Neuroinflammatory mechanisms in Alzheimer’s disease: basic and clinical research (Ed.: Rogers J), Birkhäuser Verlag, Basel, Switzerland, 2001, 121-43.
    • Möller HJ, Hampel H, Padberg F. Nootropika / Antidementiva. In: Depression und Kognition im Alter (Ed.: Hegerl U, Zaudig M, Möller HJ), Springer Verlag, Vienna, Austria, 2001, 101-24.
    • Kötter HU, Stübner S, Hegerl U, Hampel H. Biologische Untersuchungen in der Differentialdiagnostik kognitiver und depressiver Erkrankungen. In: Depression und Kognition im Alter (Ed.: Hegerl U, Zaudig M, Möller HJ), Springer Verlag, Vienna, Austria, 2001, 59-78.
    • Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Galasko D, Parnetti L, Sindic CJM, Arai H, Riemenschneider M, Hampel H, Pottel H, Valgaeren A, Hulstaert F, Vanderstichele H. CSF-phospho-tau (181 P) as a promising marker for discriminating Alzheimer disease from dementia with Lewy bodies. In: Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics (Ed.: Iqbal K, Sisodia S, Winblad B, Wisniewski HM), John Wiley & Sons, Ltd, Chichester, 2001, 286-91.
    • Hampel H, Teipel SJ, Möller HJ. Perspektiven bildgebender Verfahren in der Beurteilung leichter kognitiver Störungen und in der Frühdiagnose der Alzheimer Demenz. In: Leichte kognitive Störungen – Definition, Früherkennung und Frühbehandlung (Ed.: Kern AO, Beske F), Schriftenreihe des Instituts für Gesundheits-System-Forschung, Kiel, 2000, Bd. 83:41-7.
    • Satzger W, Ingrassia G, Nolde T, Bürger K, Hampel H, Engel R. Die CERAD-Batterie als neuropsychologisches Demenzscreening bei depressiven und dementen Patienten (Ed.: Maier W, Engel RR, Möller HJ). In: Methodik von Verlaufs- und Therapiestudien in Psychiatrie und Psychotherapie, Hogrefe Verlag, Göttingen, 2000, 197-9.
    • Teipel SJ, Hampel H. Neuropsychologie und funktionelle Bildgebung bei der Alzheimer Demenz. In: Psychopathologie und Neuropsychologie der Demenz (Ed.: Calabrese P und Förstl H. Pabst Science Publishers, 2000, 117-39.
    • Padberg F, Möller HJ, Hampel H. Pharmakotherapie dementieller Erkrankungen. In: Pharmakotherapie psychiatrischer Erkrankungen. 2. Auflage (Ed.: Möller HJ), Thieme Verlag, 2000, 517-41.
    • Hampel H. MRI based measurement of corpus callosum atrophy indicates loss of interhemispheric connectivity in Alzheimer’s disease. Forschung und Klinik an der Schwelle zum 3. Jahrtausend: aus der Arbeit der Jung-Foundation für Wissenschaft und Forschung, Volume 9 (Ed.: Siegenthaler W, Haas R), Thieme Verlag, Stuttgart, New York, 2000.
    • Frölich L, Hampel H, Gorriz C, Schramm U. Cholinerge Behandlungstrategien. In: Alzheimer Demenz: Grundlagen, Klinik, Therapie (Ed.: Förstl H), Springer Verlag, 1999, 179-90.
    • Hampel H, Möller HJ. Tacrin. In: Neuro-Psychopharmaka Bd. 5, 2. Auflage (Ed.: Riederer, Laux, Pöldinger), Springer Verlag, Vienna, New York, 1999, 705-13.
    • Padberg F, Bürger K, Hampel H. Genetische Marker und Liquorparameter der Alzheimer Demenz. In: Psychiatrie für die Praxis 30: Der demente Patient. Diagnose, Therapie, Versorgung (Ed.: Möller HJ, Förstl H, Kapfhammer HP), Urban & Vogel Verlag, 1999, 21-40.
    • Hampel H. 4 Fallberichte aus der Praxis. Die Therapie mit Aricept – 48 Fälle aus der Praxis (Ed.: und Verlag: Fa. Eisai GmbH), Frankfurt, 1999.
    • Hampel H, Bürger K, Padberg F, Bahro M. Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz. Alzheimer Demenz: Grundlagen, Klinik und Therapie. (Ed.: Förstl H, Bickel H, Kurz A.), Springer Verlag, 1999, 153-66.
    • Hampel H, Kötter HU. Liquordiagnostik. Handbuch Morbus Alzheimer. Neurobiologie, Diagnose und Therapie (Ed.: Weiss S, Weber JS), Beltz Psychologie Verlags Union, Weinheim 1997, 689-753.
    • Hock C, Müller-Spahn F, Schuh-Hofer S, Ghidau A, Börner E, Hofmann M, Hampel H, Dirnagel U, Villringer A. Nicht-invasive Messung der zerebralen Hämoglobin-Oxygenierung mit Hilfe der Nah-Infrarot-Spectroskopie beim normalen Altern und bei der Alzheimer Demenz. In: Aktuelle Perspektiven der Biologischen Psychiatrie (Ed.: Möller HJ, Müller-Spahn F, Kurtz G), Springer Verlag, Vienna 1996.
    • Hock C, Golombowski S, Naser W, Hofmann M, Hampel H, Müller-Spahn F. Elisa-Quantifizierung von Amyloid Precursor Protein, b-Amyloid und Tau-Protein – potentielle Liquor-Marker bei Patienten mit Alzheimer Demenz. In: Aktuelle Perspektiven der Biologischen Psychiatrie (Ed.: Möller HJ, Müller-Spahn F, Kurtz G), Springer Verlag, Vienna 1996, 58-61.
    • Müller-Spahn F, Klages U, Hofmann M, Hampel H, Hock C. Biologische Befunde zur Differentialdiagnose der Demenz und Depression. In: Aktuelle Perspektiven der Biologischen Psychiatrie (Ed.: Möller HJ, Müller-Spahn F, Kurtz G), Springer Verlag, Vienna 1996, 49-57.
    • Mager T, Hampel H, Edelhuber B, Weis S, Pfluger F, Hock C, Müller-Spahn F, Möller HJ. Bedeutung der MR-gestützten Volumetrie für die Psychiatrie. In: Aktuelle Perspektiven der Biologischen Psychiatrie (Ed.: Möller HJ, Müller-Spahn F, Kurtz G), Springer Verlag, Vienna 1996, 717-21.
    • Hampel H, Haberl A, Ackenheil M, Müller-Spahn F, Hock C. Blut-, Hirn-, Schrankenstörung und erhöhter Liquor Immunglobulinspiegel bei Patienten mit Demenz vom Alzheimer Typ, Multi-Infarkt Demenz und Depression. In: Aktuelle Perspektiven der Biologischen Psychiatrie (Ed.: Möller HJ, Müller-Spahn F, Kurtz G), Springer Verlag, Vienna 1996, 79-82.
    • Hampel H, Berger C, Keiler BD, Hock C, Müller-Spahn F. Erschwerte orale Antikoagulation durch mögliche Arzneimittelinteraktion zwischen Amitryptilin und Phenprocoumon. In: Aktuelle Perspektiven der Biologischen Psychiatrie (Ed.: Möller HJ, Müller-Spahn F, Kurtz G), Springer Verlag, Vienna 1996, 224-27.
    • Hampel H. Ein- und zweidimensionale Gelelektrophorese von postmortalem zerebralem Gewebe bei schizophrenen Erkrankungen: Nachweis immunomodulatorisch wirksamer Proteine. Dissertationsschrift der Medizinische Fakultät der Ludwig-Maximilian University Munich, Munich 1996.

Books (Editor) (8):

  1. Hampel H, Carrillo MC (Eds.). Alzheimer's Disease – Modernizing Concept, Biological Diagnosis and Therapy. Advances in Biological Psychiatry, Vol. 28. Karger Verlag, Basel, Switzerland, 2012, 1-193.
  2. Freitag CM, Barocka A, Fehr C, Grube M, Hampel H (Eds.). Depressive Störungen über die Lebensspanne. Ätiologie, Diagnostik und Therapie. Kohlhammer, Stuttgart, Germany, 2012, 1-218.
  3. Hampel H, Trojanowski JQ (Eds.). Biological Markers for Neurodegenerative Diseases. Progess in Neurobiology, Special Issue (vol. 95, no. 4). Elsevier, Amsterdam, The Netherlands, 2011, pp. 491-728.
  4. Rupprecht R, Hampel H (Eds.). Textbook of Psychiatry and Psychotherapy (Roter Faden – Psychiatrie und Psychotherapie, nach der neuen ÄAppO) (Dementia). Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, 2006, 1-640.
  5. Möller HJ, Hampel H, Hirsch RD, Gutzmann H, Kortus R, Teising M (Ed.). Gerontopsychiatrie als interdisziplinäre Aufgabe, Schriftenreihe der Deutschen Gesellschaft für Gerontopsychiatrie und -psychotherapie, Band 5, Berlin, Bonn, Frankfurt, Saarbrücken, Germany, 2004, 1-406.
  6. Bergener M, Hampel H, Möller HJ, Zaudig M (Ed.). Textbook of Geriatric Psychiatry (Gerontopsychiatrie: Grundlagen, Klinik und Praxis). Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, 2005, 1-790.
  7. Hampel H, Padberg F, Möller HJ (Ed.). Textbook of Alzheimer’s disease – progression, diagnosis, therapeutic strategies (Alzheimer Demenz – Klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien). Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, 2003, 1-503.
  8. Schwabe U, Paffrath D (Ed.). Psychopharmacology Report 2004. Springer-Verlag, Berlin Heidelberg, Germany, jährliche Neuauflagen von 2004-2013, 1-1.271 pages, (Advisor to the Editors).
Abstracts to Scientific Meetings (>500) examples, not complete
  1. Harald Hampel, Bruno Dubois, Ian McKeith, John O'Brien, Oscar Lopez, Oskar Hansson, Richard Pither, Rik Vandenberghe, Simone Lista. The evaluation of mTOR pathway dysregulation as a novel blood-based phenotypic risk biomarker for the assessment of Alzheimer's Disease and dementia. Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Session title: Advances in Alzheimer's Disease Blood Based Biomarker Science. Presentation number: F5-02-01. (Imaging Consortium Posters – Abstract / Poster)
  2. Michel Thiebaut de Schotten, Hovagim Bakardjian, Simone Lista, Stefan Teipel, Martin Dyrba, Massimo Filippi, Giovanni B Frisoni, Andreas Fellgiebel, Arun Bokde, Stefan Klöppel, Lutz Froelich, Fred erik Barkhof, Bruno Dubois, Harald Hampel. Advanced Diffusion Weighting Imaging (DWI) Tractography of the limbic system: Novel biomarkers of neurodegenerative changes during progression/conversion from cognitive normality to AD dementia. 2014 Alzheimer's Imaging Consortium, Copenhagen, Denmark. Presentation number: IC-P-067. Session date: July 12, 2014.
  3. Michel Thiebaut de Schotten, Hovagim Bakardjian, Simone Lista, Stefan Teipel, Martin Dyrba, Massimo Filippi, Giovanni B Frisoni, Andreas Fellgiebel, Arun Bokde, Stefan Klöppel, Lutz Froelich, Frederik Barkhof, Bruno Dubois, Harald Hampel. Advanced Diffusion Weighting Imaging (DWI) Tractography of the limbic system: Novel biomarkers of neurodegenerative changes during progression/conversion from cognitive normality to AD dementia. Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Presentation number: P2-192.
  4. Hovagim Bakardjian, Harald Hampel, Michel Thiebaut de Schotten, Simone Lista, Stéphane Epelbaum, Bruno Dubois. Functional EEG Biomarker Battery for Early-Stage Prediction of Alzheimer's Disease in Asymptomatic-At-Risk Amyloid-Positive Elderly Individuals. Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Presentation number: O3-13-04.
  5. Ivania Alves, Stephane Epelbaum, Anne Bertrand, Simone Lista, Harald Hampel, André Mauès de Paula, Charles Duyckaerts, Bruno Dubois2 Agreement, sensitivity and specificity between the neuropathological and clinical diagnoses of Alzheimer's disease (AD) dementia: A multicenter longitudinal study. Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Presentation number: P1-309.
  6. Stefan Teipel, Giovanni B. Frisoni, Martin Dyrba, Andreas Fellgiebel, Massimo Filippi, Harald Hampel. The European DTI Study in Dementia - a novel framework to test the diagnostic use of DTI in Alzheimer's disease. Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Presentation number: P3-185.
  7. Francesca Di Stefano, Stephane Epelbaum, Nicola Coley, Christelle Cantet, Hovagim Bakardjian, Simone Lista, Harald Hampel, Bruno Vellas, Bruno Dubois, Sandrine andrieu. Free and Cued Selective Reminding Test (FCSRT) performance in the prediction of Alzheimer's disease dementia: Data from a large prevention trial (GuidAge). Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Presentation number: P3-245.
  8. Ronald Lautner, Tobias Skillbäck, Mikael Landén, Giovanni B Frisoni, Jonathan A Prince, Sanna-Kaisa Herukka, Harald Hampel, Anders Wallin1, Sanna Neselius, Oskar Hansson, Lennart Minthon, Niklas Mattsson, Kaj Blennow, Henrik Zetterberg. APOE genotype and CSF Aβ42 in cognitively healthy individuals. Alzheimer's Association International Conference (AAIC 14), Copenhagen, Denmark, July 12-17 2014. Presentation number: P4-063.
  9. Ingo Kilimann, Stefan J. Teipel, Michel Grothe, Helmut Heinsen, Martin Wegrzyn, Thomas Meindl, Giovanni B. Frisoni, Arun L.W. Bokde, Andreas Fellgiebel, Massimo Filippi, Harald Hampel Stefan Klöppel10, Karlheinz Hauenstein, and the EDSD study group. Combining Morphometric Measurements of the Basal Forebrain Cholinergic System and the Cortical Thickness for Better Diagnostic Accuracy. Alzheimer's Association International Conference (AAIC 13), Boston, United States, July 13 - 18, 2013.
  10. Dyrba, Ewers, Wegrzyn, Plant, Oswald, Pievani, Bokde, Fellgiebel, Filippi, Frölich, Barkhof, Hampel, Klöppel, Hauenstein, Kirste, Teipel: Predicting prodromal Alzheimer's disease in subjects with mild cognitive impairment using multicenter diffusion tensor imaging data and machine learning algorithms: Alzheimer's Association International Conference (AAIC 13), Boston, United States, July 13 - 18, 2013.
  11. Dyrba M, Ewers M, Wegrzyn M, Kilimann I, Plant C, Oswald A, Meindl T, Frisoni G, Bokde  A, Fellgiebel A, Filippi M, Hampel H, Klöppel S, Hauenstein K, Kirste T, Teipel S, and the EDSD study group. Automatic detection of Alzheimer’s disease in multicenter DTI data. Alzheimer's Association International Conference (AAIC 12). Vancouver, Canada, July 14-19, 2012.
  12. Kilimann I, Grothe M, Heinsen H, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Klöppel S, Teipel SJ. Multicentre stability, diagnostic accuracy and regional specificity of atrophy of the cholinergic basal forebrain in Alzheimer’s disease: an EDSD study. Alzheimer's Association International Conference (AAIC). Vancouver, Canada, July 14-19, 2012.
  13. Lautner R, Zetterberg H, Blennow K, Wallin A, Herukka SK, Hampel H, Rujescu D, Ewers M, Hansson O, Mattsson N. The effects of APOE genotype on the diagnostic accuracy of CSF biomarkers for Alzheimer’s disease. Alzheimer's Association International Conference (AAIC). Vancouver, Canada, July 14-19, 2012.
  14. Lista S, Prvulovic D, Faltraco F, Hampel H. Epigenetic mechanisms of nitric oxide and in vivo brain functional imaging. Alzheimer's Association International Conference (AAIC). Vancouver, Canada, July 14-19, 2012.
  15. O’Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H. Reduced volume of hippocampus in ApoE4 carriers: an MRI study. Alzheimer's Association International Conference (AAIC). Vancouver, Canada, July 14-19, 2012.
  16. Ramakers IH, Verhey FR, Vos S, Koehler S, van Praag L, Scheltens P, Hampel H, Soininen H, Olde Rikkert M, Verbeek MM, Spiru7L, Wahlund LO, Minthon L, Tsolaki M, Blennow K, Visser PJ. Cerebrospinal fluid biomarkers for Alzheimer’s disease and specific cognitive decline in subjects with mild cognitive impairment. Alzheimer's Association International Conference (AAIC). Vancouver, Canada, July 14-19, 2012.
  17. Matura S, an de Ven V, Prvulovic D, Miller J,  Scheibe M, O’Dwyer L,Fußer F,Karakaya T, Magerkurth J, Oertel-Knöchel V, Rujescu D, Faltraco F, Hampel H. Effects of the Apolipoprotein E genotype on intrinsic functional connectivity in young healthy adults. International Conference on Alzheimer's Disease (ICAD), Dubai, January 29-31, 2012.
  18. Vos S, van Rossum I, Verhey F, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, van der Flier W, Teunissen C, Blennow K, Scheltens P, Visser PJ. CSF Markers for predicting Alzheimer-type dementia in subjects with amnestic versus non-amnestic mild cognitive impairment. International Conference on Alzheimer's Disease (ICAD), Dubai, January 29-31, 2012.
  19. Bartley M, Bokde A, Ewers M, Faluyi Y, Hampel H, O'Neill D. Do premorbid IQ and white matter hyperintensities affect executive function in healthy older people? 59th Annual Irish Gerontology Society Conference, Dublin, September 9–10, 2011.
  20. Elias-Sonnenschein L, Visser PJ, Verhey F, Graff C, Frisoni G, Scheltens P, Nobili FM, Damian M, Soininen H, Spiru L, Jones RW, Olde Rikkert M, Wilcock G, Hampel H, Ramakers I. Neuropsychiatric symptoms associated with the APOE-ε4 allele in subjects with mild cognitive impairment in the DESCRIPA and ADNI cohorts. 15th International Congress of the International Psychogeriatric Association, The Hague, The Netherlands, September 6–9, 2011.
  21. Ramakers IHGB,. Verhey FRJ, Scheltens P, Hampel H, Soininen H, Olde Rikkert M Verbeek MM, Spiru L, Wahlund LO, Minthon L, Tsolaki M, Blennow K, Visser PJ. The effect of key in vivo biomarkers for Alzheimer’s disease in cerebrospinal fluid on specific cognitive decline in subjects with mild cognitive impairment. 15th International Congress of the International Psychogeriatric Association, The Hague, The Netherlands, September 6–9, 2011.
  22. Santos AN, Hampel H, Ewers M, Prvulovic D, Minthon L, Blennow K, Hansson O. ¨¨¨. Amyloid Fibrils, Prions and Precursors: Molecules for Targeted Intervention, Halle (Saale), Germany, August, 25–28, 2011.
  23. Buschert V, Giegling I, Merensky W, Jolk S, Teipel SJ, Hampel H, Rujescu D, Buerger K. Long-term effects of a multicomponent cognitive intervention in amnestic mild cognitive impairment (AMCI). Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  24. Elias-Sonnenschein L, Verhey FRJ, Graff C, Frisoni G, Scheltens P, Nobili FM, Damian M, Soininen H, Spiru L, Jones R, Olde Rikkert M, Wilcock G, Hampel H. APOE-ε4 allele and neuropsychiatric symptoms in MCI: Findings from the DESCRIPA study. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  25. Faltraco F, Prvulovic D, Ewers M, Müller J, Rujescu D, Hampel H. PICALM single nucleotide polymorphisms are associated with CSF Aß1-42 levels in patients with Alzheimer’s dementia. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  26. Fellgiebel A, Gartenschläger M, Schreckenberger M, Hampel H, Yakushev I. Revised diagnostic criteria for Alzheimer’s disease: Impact of different supportive biomarkers on early diagnosis. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  27. Hampel H. Blood, plasma and serum biomarkers of preclinical Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  28. Hampel H, Miller J, Scheibe M, Fusser F, Matura S, Oertel-Knöchel V, Karakaya T, Magerkurth J, Prvulovic D. Effects of the apolipoprotein E genotype on memory performance and brain morphology in young healthy adults. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  29. Krause K, Franzmann J, Hampel H. Assessment of caregiver’s social competencies in dementia care: Development and validation of a self-report instrument. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  30. O’Dwyer L, Lamberton F, Bokde A, Ewers M, Tanner C, Mazoyer B, Faluyi Y, O’Neill D, Bartley M, Collins R, Coughlan T, Prvulovic D, Hampel H. Diffusion tensor imaging identifies hotspots of white matter damage in Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  31. Ramakers I, Soininen H, Visser PJ and ADNI, Blennow K, Verhey FRJ, Olde Rikkert M, Shaw LM, Hampel H, Spiru L, Trojanowski JQ, Scheltens P, Verbeek MM, Aalten P. Anxiety is related to Alzheimer’s disease markers in cerebrospinal fluid of subjects with mild cognitive impairment. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  32. Shen Y, Sabbagh M, Nural H, He P, Cheng X, Ewers M, Zhong J, Leyhe T, Wallin A, Blennow K, Li R, Hampel H. Significant elevation of plasma BACE in AD and MCI patients. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  33. Teipel S, Hampel H, Grothe M, Heinsen H. In vivo imaging of cholinergic structural degeneration in Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  34. van Rossum I, Burns L, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Verhey FRJ, L’Italien G, Van der Flier W, Teunissen C, Blennow K, Wolz R, Visser PJ. High CSF tau predicts rapid decline to AD-type dementia in MCI subjects with abnormal CSF Aß1-42. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  35. van Rossum I, Soininen H, Frölich L, Visser PJ, Scheltens P, Blennow K, Verhey FRJ, Frisoni G, Hampel H, Wahlund LO, Wolz R, Van der Flier W, Tsolaki M, Nobili F, Minthon L. Predictive accuracy for Alzheimer’s disease of CSF Aß1-42, hippocampal atrophy and APOE genotype in MCI subjects depends on age. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  36. Vos S, Soininen H, Visser PJ, Blennow K, Verhey F, Burns L, Hampel H, Wahlund LO, Wolz R, Scheltens P, Van der Flier W, Tsolaki M, Teunissen C, Minthon L, L’Italien G. CSF and MRI biomarkers as predictors for Alzheimer’s-type dementia in subjects with mild cognitive impairment. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  37. Vos S, Verhey F, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni G, Frölich L, Nobili F, Van der Flier W, Blennow K, Wolz R, Visser PJ. CSF, MRI, and APOE biomarkers as predictors for Alzheimer-type dementia in subjects with amnestic versus non-amnestic mild cognitive impairment. Alzheimer’s Association International Conference (AAIC) 2011, Paris, France, July, 16th–21st, 2011.
  38. Hampel H. Wege zur Positivdiagnostik der AD – Entwicklung neuer Kriterien, Biomarker und neurobiologische Hintergründe. Interdisziplinäre Neurogeriatrie. 2011; 8(Suppl):S14-5. 10. Kongress der Deutschen Gesellschaft für Gerontopsychiatrie und -psychotherapie, Berlin, May 11-13, 2011.
  39. Hampel H. Embracing the evolution of diagnostic tools in everyday practice. (Abstract Booklet, p. 10.) Changing times in Alzheimer's care: Overcoming Challenges and Empracing Advances, Munich, April 8–9, 2011.
  40. Menchola M, Bergfield KL, Hanson KD, Chen K, Lin L, Teipel SJ, Hampel H, Rapoport SI, Moeller JR, Alexander GE. Relative effects of Alzheimer’s disease and healthy aging on regional network patterns of MRI gray matter volume. Society for Neuroscience Annual Meeting, Chicago, USA, October, 17th–21th, 2009.
  41. Teipel SJ, Friese U, Meindl T, Herpertz S, Reiser M, Hampel H. Diagnostic utility of diffusion tensor imaging and deformation-based morphometry for the assessment of Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  42. Bokde A, Ewers M, Lopez-Bayo P, Born C, Meindl T, Teipel SJ, Reiser M, Moeller HJ, Hampel H. Functional connectivity alterations of visual processing in Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  43. Teipel SJ, Meindl T, Hampel H. Cortical disconnection in Alzheimer disease: insights from diffusion tensor imaging. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  44. Ewers M, Faluyi Y, Buerger K, Teipel SJ, Bokde ALW, Hampel H. Lower body mass index associated with higher CSF-levels of tau pathology in Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  45. Buerger K, Schneider P, Friese U, Merensky W, Buschert VC, Hampel H, Teipel SJ. Plasma Aß42 / Aß40 ratio is decreased in amnestic mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  46. Schneider P, Putz S, Hartmann O, Hein F, Bergmann A, Hampel H, Buerger K. Blood-based microcirculation markers in Alzheimer’s disease – diagnostic value of CT-proET-1 in patients with amnestic mild cognitive impairment. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  47. Ewers M, Bokde ALW, Walsh C, Hampel H, Alzheimer’s Disease Neuroimaging Initiative. Multidimensional biomarker-based diagnosis of early AD. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  48. Schwarz MJ, Guillemin G, Teipel S, Buerger K, Hampel H. Elevated 3-Hydroxykynurenine serum levels in Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  49. Foerster S, Buschert VC, Buchholz HG, Teipel SJ, Zach C, Hampel H, Bartenstein P, Buerger K. Positive effects of a 6-months stage-specific cognitive intervention program on brain metabolism in subjects with amnestic mild cognitive impairment (aMCI) and mild Alzheimer’s disease (AD). International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  50. Buschert VC, Friese U, Merensky W, Teipel SJ, Hampel H, Buerger K. Effects of a stage-specific cognitive intervention program in patients with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  51. Wagner M, Meindl T, Alexander G, Hennig-Fast K, Buerger K, Benninghoff J, Engel R, Reiser MF, Moeller HJ, Hampel H, Teipel SJ. Subcortical fiber tract integrity and the CERAD cognitive battery in patients with Alzheimer’s disease: a multivariate approach to detect morphological correlates of cognitive failure. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  52. Bokde A, Ewers M, Faluyi Y, Delaney C, Khattack A, Collins R, Kerskens C, Coughlan T, Nibrihain S, Daly I, Swanwick G, O’Neill D, Hampel H. Alterations in activation between mild cognitive impaired subjects during a working memory task and resting coherent network. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  53. Shen Y, Sabbagh M, Nural H, He P, Cheng X, Ewers M, Hampel H. Significantly altered BACE1 levels have been found in the blood of AD and MCI subjects. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  54. Likitjaroen Y, Meindl T, Wagner M, Buerger K, Hampel H, Teipel SJ. Twelve months follow-up study of fractional anisotropy changes in mild cognitive impairment compared to healthy elderly subjects. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  55. Du Y, Wei X, Dodel R, Hampel H, Farlow M, Zheng W. The choroid plexus is involved in antibody-induced beta-amyloid clearance. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  56. Norberg J, Almkvist O, Graff C, Frisoni GB, Froelich L, Hampel H, Jones R, Kehone P, Minthon L, Nobili F, Olde-Rikkert M, Rigaud AS, Soininen H, Spiru L, Tsolaki M, Vellas B, Elias-Sonnenschein L, Scheltens P, Wahlund LO, Verhey FRJ, Visser PJ. Relation between APOE ε4 allele and MCI is modulated by geographical region. Results from the DESCRIPA study. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  57. Thambisetty M, Resnick SM, Ferrucci L, Wong D, Zhou Y, Lovestone S on behalf of the AddNeuroMed Consortium, National Institute on Aging, Clustering is a plasma biomarker of severity, progression and pathology in Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2009 of the Alzheimer’s Association, Vienna, Austria, July, 11th–16th, 2009.
  58. Frisoni GB, EADC-ADNI Working Group for Harmonization of Hippocampal Volumetry. Development of a harmonized protocol for the manual tracing of the hippocampus: an EADC-ADNI joint effort. XIX. IAGG World Congress of Gerontology and Geriatrics, Paris, France, July, 05th–09th, 2009.
  59. Hampel H. The role of CSF biomarkers in the identification of AD at pre-dementia stages. 9th World Congress of Biological Psychiatry, Paris, France, June, 28th–July, 02th, 2009.
  60. Bede P, Doherty C, Ewers M, Bokde A, Hampel H, Hardiman O. High resolution 3 Tesla structural, functional and metabolic imaging of the brain in Amyotrophic lateral sclerosis; correlation with comprehensive neuropsychological profiling. European ALS Congress, Turin, Italy, May, 22th–24th, 2009.
  61. Hampel H. Gegen das Vergessen möglichst früh behandeln. Deutsche Apotheker Zeitung. 2009; 149:74. Interpharm 2009,Hamburg, Germany, March 27th–29th, 2009.
  62. Carlson AM, Schneider P, Hampel H, Fellerer K, Buerger K, Haass C, Capell A. Progranulin as a biomarker for frontotemporal lobar degeneration and Alzheimer’s diseae. AD/PD Conference, Prague, Czech Republic, March, 11th–15th, 2009.
  63. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, De Meyer G, Shapiro F, Wolf S, Bibl M, Witlfang J. Amyloid β peptides in plasma as a potential tool for the early diagnosis of Alzheimer’s disease: a multicenter study with a novel multiplexing assay. AD/PD Conference, Prague, Czech Republic, March, 11th–15th, 2009.
  64. Edgin JO, Hanson KD, Chen K, Bergfield K, Nadel L, Teipel SJ, Hampel H, Rapoport SI, Schapiro MB, Alexander GE. Regional network of MRI gray matter reductions associated with aging in non-demented adults with Down syndrome. Neuroscience 2008, the 38th Annual Meeting of the Society for Neuroscience, Washington, DC, USA, November, 15th–19th, 2008.
  65. Teipel SJ, Meindl T, Ewers M, Hampel H, Herpertz SC, Meindl T. Integrated neuroimaging of dementia. Eur Arch Psy Clin N. 2008; 258(Suppl 4):S-06-03. 7th Three-Country-Symposium for Biological Psychiatry, Göttingen, Germany, October, 09th–11th, 2008.
  66. Teipel SJ, Ewers M, Hampel H. Structural imaging for early diagnosis and mapping of treatment effects in Alzheimer’s disease. Eur Arch Psy Clin N. 2008; 258(Suppl 4):S-01-05. 7th Three-Country-Symposium for Biological Psychiatry, Göttingen, Germany, October, 09th–11th, 2008.
  67. Verwey NA, Blennow K, Clark C, Cole GM, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, v. Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Blankenstein MA. Clinical Trial Conference on Alzheimer’s Disease (CTAD), Montpellier, France, September 17th–19th, 2008.
  68. Förster S, Teipel SJ, Zach C, Hampel H, Bartenstein P, Bürger K. Cortical functional representation of visuo-constructive abilities in patients with Alzheimer’s disease. 81. Kongress der Deutschen Gesellschaft für Neurologie mit Fortbildungsakademie, Hamburg, Germany, September 10th–13th, 2008.
  69. Hampel H, Ewers M, Zhong Z, Bürger K, Wallin A, Du Y, Blennow K, Shen Y. Alteration of beta-secretase (BACE1) functional candidate biomarkers in subjects with mild cognitive impairment and Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  70. Ewers M, Bokde ALW, Teipel SJ, Beil S, Born C, Hampel H. Altered hippocampus functional connectivity in the recognition memory network corrected for grey matter atrophy in mild cognitive impairment. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  71. Bokde ALW, Karmann M, Born C, Teipel SJ, Omerovic M, Reiser MF, Möller HJ, Hampel H. Altered brain activation during verbal working memory in mild cognitive impaired subjects. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  72. Bokde ALW, Karmann M, Born C, Teipel SJ, Frank G, Reiser MF, Möller HJ, Hampel H. Alteration in activation during encoding and recognition of words in mild cognitive impaired subjects: a mixed block/event related fMRI study. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  73. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe M, Kraft I, Gasser T, Leyhe T, Kurz A, Basun H. Lithium trial in Alzheimer’s disease: A randomized, single-blinded, placebo-controlled, parallel-group multicentre 10-week study. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  74. Teipel SJ, Ewers M, Wolf S, Jessen F, Peters O, Born C, Kornhuber J, Hampel H. Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer’s disease: a longitudinal study. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  75. Teipel SJ, Pogarell O, Meindl T, Hampel H. Neuronal networks underlying interhemispheric connectivity in healthy aging and amnestic mild cognitive impairment. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  76. Källen A, Christiansson M, Sävman K, Andreasson U, Simon AJ, Hampel H, Blennow K, Zetterberg H. Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in term and pre-term newborn infants. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  77. Li R, Zhong J, Chen X, Song Y, Lee T, Pierce N, Ewers M, Blennow K, Hampel H. Beta-secretase levels changed in mild cognitive impairment patients’ brains and cerebral spinal fluid. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  78. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H. Increased CSF-BACE1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer’s disease. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  79. Bokde ALW, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, Möller HJ, Hampel H. Decreased activation along the dorsal visual pathway after three month treatment with Galantamine in mild Alzheimer’s disease: a fMRI study. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  80. Du Y, Wei X, He Y, Wei G, Hampel H, Dodel R, Farlow M. Identification and characterization of human autoantibodies that may be used for the treatment of prion diseases. International Conference on Alzheimer’s Disease (ICAD) 2008 of the Alzheimer’s Association, Chicago, USA, July 26th–31th, 2008.
  81. Bokde A, Lopez-Bayo P, Meindl T, Teipel SJ, Reiser M, Möller HJ, Hampel H. Effect of rivastigmine in a double-blind study in MCI subjects: A functional magnetic resonance imaging study. Int J Neuropsychoph. 2008; 11(Suppl 1):S29-S30. XXVI. CINP Congress – collegium internationale neuro-psychopharmacologicum. 50. Anniversary of the CINP, Munich, Germany, July, 13th–17th, 2008.
  82. Bokde A, Karmann M, Born C, Teipel SJ, Omerovic M, Reiser M, Möller HJ, Hampel H. Altered brain activation during verbal working memory in mild cognitive impaired subjects. Int J Neuropsychoph. 2008; 11(Suppl 1):S171. XXVI. CINP Congress – collegium internationale neuro-psychopharmacologicum. 50. Anniversary of the CINP, Munich, Germany, July, 13th–17th, 2008.
  83. Uspenskaya O, Heinzel S, Teipel SJ, Hampel H, Buerger K. Longitudinal changes of cerebrospinal fluid biomarkers in patients with Alzheimer’s disease and mild cognitive impairment. Int J Neuropsychoph. 2008; 11(Suppl 1):S171-S172. XXVI. CINP Congress – collegium internationale neuro-psychopharmacologicum. 50. Anniversary of the CINP, Munich, Germany, July, 13th–17th, 2008.
  84. Förster S, Teipel SJ, Zach C, Hampel H, Bürger K, Bartenstein P. F18-FDG-PET and cortical representation of visuo-spatial abilities in patients with Alzheimer’s disease. 55th Annual Meeting of the Society of Nuclear Medicine (SNM), New Orleans, USA, June 14th–18th, 2008.
  85. Hampel H. Development of biochemical markers of Alzheimer’s disease. 2008 IPA European Meeting in Association with the Faculty of Old Age Psychiatry of the Royal College of Psychiatrists, Dublin, Ireland, April 08th–11th, 2008.
  86. Wei X, He Y, Tan J, Dodel R, Hampel H, Farlow M, Du Y. Human Anti-Prion Protein antibodies block A117V PRP peptide fibril formation and prevent A117V PRP peptide-induced neurotoxicity. Eur Psychiat. 2008; 23(Suppl 2):S39. The 16th European Congress of Psychiatry of the Association of European Psychiatrists (AEP), Nice, France, April 05th–09th, 2008.
  87. Hampel H. Biochemical and neuroimaging markers in MCI and early Alzheimer’s disease. Int Psychogeriatr. 2007; 19(Suppl 1):S32-1. Silver Congress of the International Psychogeriatric Association. Osaka, Japan, October 14th–18th, 2007.
  88. Shen Y, Zhong Z, Ewers M, Teipel S, Buerger K, Wallin A, Blennow K, Hampel H. The levels of Beta-Secretase (BACE1) in cerebrospinal fluid of mild cognitive impairment. Int Psychogeriatr. 2007; 19(Suppl 1):S32-4. Silver Congress of the International Psychogeriatric Association. Osaka, Japan, October 14th–18th, 2007.
  89. Shen Y, Ewers M, Teipel S, Buerger K; Wallin A, Blennow K, Zhong Z, He P, McAllister C, Hampel H. Levels of Beta-Secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Int Psychogeriatr. 2007; 19(Suppl 1):FC10-6. Silver Congress of the International Psychogeriatric Association. Osaka, Japan, October 14th–18th, 2007.
  90. Buerger K, Ernst A, Ewers M, Omerovic M, Morgenthaler NG, Knauer K, Bergmann A, Hampel H. Blood based biomarkers indicate disturbances of microcirculation in Alzheimer’s disease. Research Festival, Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany, July 27th, 2007.
  91. Teipel SJ, Born C, Ewers M, Bokde ALW, Reiser MF, Möller HJ, Hampel H. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer’s disease in mild cognitive impairment. Research Festival, Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany, July 27th, 2007.
  92. Sydykova D, Teipel SJ, Stahl R, Dietrich O, Reiser MF, Schönberg S, Hampel H, Bürger K. Correlations between CSF levels of tau protein and fiber tract integrity as measured by diffusion tensor imaging in Alzheimer’s disease. Research Festival, Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany, July 27th, 2007.
  93. Hunklinger U, Pogarell O, Sydykova D, Meindl T, Reiser M, Möller HJ, Hampel H, Teipel SJ. Correlation between fiber tract integrity and interhemispheric coherence: a combined evaluation of DTI and EEG in mild cognitive impairment and healthy aging. Research Festival, Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany, July 27th, 2007.
  94. Teipel SJ, Born C, Hampel H. Advantages of MRI. Alzheimer’s Biomarker Conference, Harvard & Washington University, Washington D.C., USA, June 9th, 2007.
  95. Selle H, Hager K, Buerger K, Hampel H, Kellmann M, Lamerz J, Lannfelt L, Möhring T, Riepe M, Schrader M, Tumani H, Zucht H-D. Die Analyse des Liquor-Peptidoms – Abbild hirnspezifischer Prozesse? Eine Annäherung am Beispiel des Morbus Alzheimer. Alzheimer’s Dementia, Abstractbuch, 2006:S14. Deutsche Gesellschaft für Alternsforschung, 16. Tagung. Karlsruhe, Germany, November 11th, 2006.
  96. Hampel H. Development of Biological Markers of Alzheimer’s Disease. 6th International Scientific Meeting of the International College of Geriatric Psychoneuropharmacology (ICGP), Hiroshima, Japan, October 4th, 2006.
  97. Hampel H. Biological Markers and MR-based Imaging Methods for Integrated Clinical Research in AD and MCI. 6th International Scientific Meeting of the International College of Geriatric Psychoneuropharmacology (ICGP), Hiroshima, Japan, October 6th, 2006.
  98. Teipel SJ, Stahl R, Dietrich O, Schoenberg SO, Perneczky R, Bokde ALW, Reiser MF, Moeller HJ, Hampel H. Multivariate network analysis of fiber tract integrity in Alzheimer’s disease. Research Festival, Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany, July 28th, 2006.
  99. Fast K, Broeder A, Aigner A, Teipel SJ, Hampel H, Engel RR, Moeller HJ. Charakteristika des Lernens und Vergessens beim gesunden und pathologischen Altern: Ein kognitiv-psychometrischer modellbasierter Ansatz. Research Festival, Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany, July 28th, 2006.
  100. Alexander GE, Chen K, Aschenbrenner M, Reiman EM, Caselli RJ, Merkley TL, Lewis DJ, Pietrini P, Teipel SJ, Hampel H, Papoport SI, Moeller JR. Regional network pattern of MRI gray matter volume in Alzheimer’s dementia.Poster presentation. ICAD, Alzheimer Imaging Consortium 2006, Madrid Spain, July 15th, 2006.

 

 

 

 

 

Autoimmune Journal Flyer